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Depressive disorders are characterised by sadness, loss of interest or pleasure, feelings of guilt 
or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration (1).  
Anxiety disorders refer to a group of mental disorders characterised by feelings of anxiety and 
fear, including generalised anxiety disorder, panic disorder, phobias, social anxiety disorder, 























Introduction: Antenatal depression and anxiety in women living with HIV are associated with 
a number of poor maternal and child outcomes, and undermine the world target of eliminating 
mother-to-child transmission (MTCT) of HIV.  Despite the importance of antenatal mental 
health, the data on the factors associated with common mental illnesses in HIV-infected women 
are limited.  Thus, the aim of the present study was to determine the prevalence and factors 
associated with depression and anxiety among pregnant women living with HIV and attending 
antenatal clinics in Kilimanjaro region, Tanzania. 
Methods: We analysed the baseline data from an ongoing cohort study of 200 pregnant women 
living with HIV and attending antenatal care in two districts of the Kilimanjaro region. Women 
were eligible for inclusion in the parent cohort study if they were HIV-infected and in their 
second or third trimester of pregnancy. Antenatal depression and anxiety were assessed using 
the Edinburgh Postnatal Depression Scale and the Brief Symptom Scale, respectively. A 
multivariate logistic regression model was used to assess the factors that were independently 
associated with anxiety, depression and comorbidity of anxiety and depression. Variables with 
a p-value less than 0.15 in univariate analysis were included in the final multivariate model. 
Results: Participants had a median (IQR) age of 30 years (26-35). About half were married 
(n=98, 49.0%) and knew their HIV status prior to the index pregnancy (n=105, 52.5%).  When 
asked whether they had disclosed their status to anyone, 159 (79.5%) had disclosed to at least 
one person and more than half (n=119/170, 70.0%) had disclosed to their sexual partner. Fifty 
(25.0%) screened positive for possible depression and this was associated with being single 
(aOR=4.0, 95% CI=1.2–13.7), food insecurity (aOR=2.6, 95% CI=1.0–6.6), and HIV shame 
(aOR=1.2, 95% CI=1.1–1.3). Of the 197 women who completed the anxiety questionnaire, 47 
(23.5%) screened positive for anxiety which was associated with being ashamed of having HIV 
(aOR=1.1, 95% CI=1.1 – 1.2). The prevalence of comorbid symptoms of depression and 
anxiety was 17.8% (n=35). HIV shame and lifetime experience of violence (aOR=3.4, 95% 
CI=1.2 – 9.6) were found to be independently associated with comorbid depression and anxiety. 
Conclusion: One in every four pregnant women living with HIV screened positive for anxiety 
and/or depression. The majority of women with depressive symptoms also had anxiety 
symptoms. In this population, a number of factors were associated with depression and anxiety. 
These factors ranged from marital status and lifetime experience of violence, food insecurity to 
HIV-related shame. In order to successfully engage women in HIV care and support their well-
 xiii 
being, prevention of MTCT (PMTCT) programmes should have strategies to screen and support 
women with mental illnesses. 
  
 1 
CHAPTER 1: INTRODUCTION 
1.1 Background  
The HIV epidemic remains a significant global health challenge.  At the end of 2016, an 
estimated 36 million people were living with HIV globally, with approximately 1.8 million new 
infections during that year (3). About 70.1% of people living with HIV/AIDS (PLHIV) are 
living in Sub-Saharan Africa, with women accounting for more than 50% of all PLHIV in the 
region (4). In Tanzania, an estimated 1.4 to 1.6 million people were living with HIV in 2012, 
with higher rates found in women (6.2%) compared to men (3.8%) (2). Although HIV affects 
people of all ages, women of childbearing age are particularly vulnerable. The prevalence of 
HIV among women attending antenatal clinics in Tanzania was reported at 6.9% (3), with 
similar rates found in urban Moshi, Tanzania at 6.0% (4). 
Not only are PLHIV more likely to have a number of physical diseases (5), they are also more 
likely to suffer from common mental disorders such as depression (6) and anxiety (7). A meta-
analysis of ten studies found depression to be nearly twice as high in PLHIV compared to those 
who are HIV-negative (8). Although depression can affect everyone, it is 2 to 3 times more 
likely to affect women than men (9). Given this higher prevalence of depression among women 
in general, it is not surprising that the prevalence of depression is also high among pregnant and 
postpartum women.  
Globally, around 15.6% of pregnant women are reported to suffer from common mental 
conditions, particularly depression  (10). Linked with proverty and social disparity, antental 
mental disorders are common in low- and middle-income countries (LMICs) compared to 
higher-income countries. A number of studies have reported a high prevalence of mental 
disorders among pregnant women in LMICs.  For example, one systematic review of studies 
conducted in LMICs reported a prevalence of 15.6% (11). More specific to pregnant women 
living in Africa, a review by Sawyer reported a prevalence of 11.3% on the continent (12).   
The current evidence supports the association between HIV infection and mental illnesses in a 
vicious cycle (13). Because of the high prevalence of HIV in Africa, it is not surprising also to 
find a high prevalence of mental disorders among women. For example, in a systematic review 
of studies among HIV-infected African women, the prevalence of antenatal depression ranged 
between 23% and 44%, more than double the rates in the general population of pregnant women 
(14). Approximately 10% to 20% of these women reported suffering from postpartum 
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depression (15).  Although there are a number of causes of depression, the available literature 
suggests that this particulary high prevalence of depression among pregnant women may be 
due to the changes in the level of estrogen and progesterone during pregnancy (10). These 
hormones exhibit neuroregulatory effects like mood and cognition. During pregnancy, the 
expected hormonal dysregulation in vulnerable HIV-positive pregnant women plays a role in 
the observed high prevalence of perinatal depression (16).   
Antenatal depression and anxiety are associated with a number of poor maternal outcomes. For 
example, one study has reported poor adherence to antiretroviral therapy (ART) among women 
with depression (17), with increased risk of vertical transmission of HIV to the fetus (18). 
Maternal depression among HIV-positive women also has an impact on infant nutrition and 
development, as evidence suggests that these children are at increased risk of growth retardation 
(19). Pregnant women with depression progress faster to the advanced stages of HIV compared 
to those without depression (20) and they are two times more likely to die from AIDS-related 
deaths, especially in LMICs (20,21). There is evidence that antenatal anxiety among HIV-
infected and uninfected women also has a negative impact on child development. For example, 
Talge and colleagues demonstrated that antenatal anxiety was associated with preterm delivery, 
low birth weight and the risk of neurodevelopment conditions such as attention deficit disorder 
(22).  
Studies from LMICs have reported a higher prevalence of depression and anxiety among 
pregnant women compared with those who are not pregnant. However, the prevalence differs 
among studies and among countries. For example, in rural South Africa, almost half (47%, 
n=51/109) of pregnant women screened positive for depression (23). However, a low 
prevalence of antenatal depression (5.3%, n=23) was reported in Zimbabwean pregnant women 
(24). Despite compelling evidence of depression and anxiety among HIV-infected pregnant 
women from high-income countries (HICs), few studies have investigated the prevalence and 
factors associated with depression and anxiety among HIV-infected pregnant women living in 
LMICs. Of particular concern is the lack of studies from Sub-Saharan Africa, a region where 
70% of the world’s HIV-positive women live (4).  A cross-sectional study in rural South Africa 
among HIV-positive pregnant women reported a 27.8% prevalence (27/109) of depression 
among this sample (23).  Kaida and colleagues observed a similar prevalence rate for depression 
in a cohort of 447 HIV-positive pregnant women in Uganda (39%) (25). Protective factors 
against perinatal depression included viral suppression, longer time on ART, better physical 
health and never having been married (25).   
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Similar to other LMICs, in Tanzania, a high prevalence of depression has been reported among 
pregnant women. In Dar es Salaam, antenatal depression was reported in 39.5% of participants 
in one study (26). However, scant data exists on mental health among pregnant women who are 
living with HIV in Tanzania. Of the four manuscripts published to date, all of them were from 
a single cohort of 891 HIV-positive pregnant women enrolled in a randomised controlled trial 
in Dar es Salaam, the largest city in Tanzania. In these studies, 42.4% to 73.4% of women met 
the criteria for antenatal depression (27,28), and a much faster HIV disease progression among 
depressed pregnant women was found (20). Given that these studies were conducted with the 
same cohort, they did not include anxiety disorders and the results are not generalisable to other 
areas of Tanzania, meaning that further research is required. The present study allowed us to 
further explore depression and anxiety among HIV-positive pregnant women.  Findings from 
the present study will add to the development, planning, and implementation of the depression 
and anxiety screening programme among HIV-infected pregnant women in Tanzania. 
Currently, the HIV care and treatment programme in the country focuses primarily on physical 
well-being, leaving women’s mental health largely unaddressed. Additional data on the burden 
of mental health disorders among this population may facilitate a greater focus on these issues 
in HIV care and treatment. 
1.2 Aims & Objectives 
Aim  
The aim of the present study is to determine the prevalence and factors associated with 
depression and anxiety among HIV-infected pregnant women attending antenatal clinics in 
Kilimanjaro region, Tanzania. 
Specific objectives 
1. To determine the prevalence of depression and anxiety among HIV-infected pregnant 
women attending antenatal clinics in Kilimanjaro region. 
2. To determine the prevalence of comorbidity of depression and anxiety among HIV-
infected pregnant women attending antenatal clinics in Kilimanjaro region. 
3. To examine factors associated with depression, anxiety and comorbidity of depression 




CHAPTER 2: LITERATURE REVIEW 
 
2.0 Introduction  
In this chapter, I will begin by describing the global burden of mental disorders, and then discuss 
the prevalence of depression and anxiety, focusing on the general population and then specific 
subgroups at risk, such as women, PLHIV and pregnant women, where appropriate.  The 
available literature investigating the prevalence of depression and anxiety among pregnant 
women who are living with HIV will be highlighted. I will also describe what is known about 
the factors associated with antenatal depression and anxiety among HIV-infected women. I will 
conclude the chapter by describing the implications of untreated depression and anxiety.  
A systematic literature search of published and unpublished studies on depression and anxiety 
was conducted. The following electronic databases were searched for studies published 
between 2000 and 2017: PubMed, Scopus, Google Scholar and African Index Medicus (AIM).  
Additionally, the WHO website, UNAIDS website and institutional repositories were searched 
for gray literature. The final search results were limited to publications in English and full text. 
For depression, the following keywords were used: ‘depression’, ‘prevalence’, ‘factors’, and 
‘pregnant’. In addition, anxiety was also searched separately using the same keywords in 
addition to ‘anxiety’.   The full search strategy is available in Appendix II. 
2.1 Global burden of depression and anxiety  
Mental disorders contribute significantly to the  global burden of disease (GBD). According to 
the 2010 GBD, the Mental Neurological and Substance Use Disorders (MNS) Disability-
Adjusted Life Years (DALYs) between 1990 and 2010 increased by 41% (29). Further, the 
increase of major depressive disorder was 37% (Murray et al. 2012). In 1990, MNS DALYs 
was 182 million while in 2010 it increased to 258 million (27). MNS contributed 10.4% of the 
total DALYs in 2010, while of the total years lived with disability (YLDs), 18.9% were due to 
mental illness. The estimates have shown variations associated with gender, whereby, women 
were more affected compared to men. The DALYs associated with depression and anxiety were 
reported to be high in women (1,161.2) compared to men (689.9) in the same age group. 
Similarly, the absolute DALYs associated with anxiety was high among women (510.3) 
compared to men (273.0) (27). Furthermore, the relative proportion of MNS DALYs to overall 
disease burden was higher (15.5%) in HICs compared to LICs (9.4%). However, the absolute 
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MNS DALYs was higher in LICs compared to HICs. Vigo and colleagues contended that the 
MNS are underestimated with the current estimates of the GBD (30). Some of the reasons for 
the underestimation are the misclassification of chronic pain syndromes with musculoskeletal 
disorders, and exclusion of personality disorders from the calculations. Additionally, less 
consideration of the contribution of severe mental illness to mortality from other causes is under 
rated. These authors re-estimated the contribution of MNS into the GBD, with 32·4% of YLDs 
and 13·0% DALYs of the GBD accounted for by MNS (30). In 2015, depression and anxiety 
only accounted for 11.6% of the total YLD in Tanzania (31). 
2.2 Prevalence of Depression and Anxiety 
2.2.1 Depression 
Globally, an estimated 322 million people are living with depression, making the disorder the 
leading mental health disorder in all age groups (31). The last world mental health survey 
(WMH) conducted in 28 countries, applying similar methodology across countries using the 
WHO Composite International Diagnostic Interview (CIDI), found that depression was the 
second most common condition after specific phobias. The lifetime prevalence of major 
depressive disorder ranged from 4% to 10%, whereas the 12-month prevalence ranged from 3% 
to 6% (32,33). Importantly, in this WMH, it was estimated that the prevalence of mental 
disorders was higher in HICs as compared to LMICs.  
A few nationally representative studies have been conducted in African countries investigating 
the prevalence of depression. For example, as part of the World Mental Health Surveys, the 
South African Stress and Health (SASH) study reported a lifetime prevalence of 9.8%. 
Surprisingly, alcohol abuse was the most prevalent (11.4%) disorder, followed by depression 
and agoraphobia without panic (9.8%) (34). Furthermore, in this survey, it was reported that 
major depressive disorders were the leading condition in the 12-month prevalence of disorders, 
with a prevalence of 4.9% (34). Surprisingly, in Nigeria, a survey with the same methodology 
and same screening tool as the SASH study found a low prevalence of depression for both the 
lifetime (3.1%) and 12-months (1.1%) (35).  
In Ethiopia, a national survey of 4925 adults aged 18 years and above reported a prevalence of 
9.1% of depression (36). Surprisingly, a study in the urban outpatient department in Ethiopia 
reported a lower prevalence compared to the national survey – 6.7% of participants experienced 
the symptoms of depression within the 12 months preceding the survey (37). In this population, 
the lifelong prevalence of major depressive mood disorder was 18.0%. The WHO has recently 
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estimated the magnitude of common mental illnesses. In their estimates,  there are about 2.1 
million cases of depression in Tanzania, making a prevalence of  4.1% (31). 
A diagnosis of depression is made using the DSM-V criteria. The DSM-V needs to be 
administered and interpreted by a physician, but in primary health facilities and in data 
collection (epidemiological studies), physicians are not typically available to make the 
diagnosis using the DSM-V. This situation limits the utilisation of DSM-V in most settings, 
with increased use of screening tools. The depression screening tools that are available are 
useful in identifying who is likely to have the disorder, although not in providing a definitive 
diagnosis. In screening for depression, there are several validated screening tools that are 
sensitive and easy to administer. These tools vary in sensitivity and specificity, which is among 
the reasons for the difference in prevalence across studies (38). In this literature review, few 
studies used DSM-IV or DSM-V in identifying participants with depression. Rather, most 
studies used screening tools, the most common being: Beck Depression Inventory (39), The 
Hospital Anxiety and Depression Scale (HADS) (40), Mini International Neuropsychiatric 
Review (41), Edinburgh Postnatal Depression Scale (42), Epidemiological Studies Depression 
Scale (43), and Hopkins Symptom Checklist (44). 
The available literature suggests that certain subgroups are more at risk for depression. This 
includes 1) women, 2) PLHIV, and 3) pregnant women. Depressive signs and symptoms are 
more common in women than in men, while men have more externalising and substance 
disorders compared to women (32). The gender differences in the prevalence of depression are 
observed both in high income countries and LMICs. For example, a review by Patel in LMICs 
found that the unipolar depressive disorder was the second most common (10.6%) mental 
disorder among women, while in men it was the third most common disorder with a prevalence 
of 6.7% (45).  
The prevalence of depression is higher among PLHIV as compared to those who are uninfected. 
In a meta-analysis of risk factors associated with depression, people living with HIV were at a 
higher risk of depression compared to people without HIV (8).  Although this meta-analysis 
included only 10 articles, and six of them only included homosexuals, one major strength was 
the inclusion of participants with confirmed depression (8). In Zimbabwe, the prevalence of 
depression was 47.3% among HIV-uninfected people as compared with a prevalence of 68.7% 
among those living with HIV (46). Several studies from South Africa have reported a similarly 
high prevalence of depression among PLHIV as compared to those who are HIV-uninfected.  
For example, Peltzer and colleagues found that 2 in every 10 HIV-infected participants screened 
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positive for depressive symptoms, whereas 1 in every 10 HIV-uninfected participants had 
positive results (47).  A further study in Johannesburg, found the prevalence of depression was 
higher among PLHIV (15.0%) compared to those who are HIV-uninfected (8.9%) (48). 
As mentioned in the background section, reports have shown that depression is common among 
pregnant women. For example, one meta-analysis of 21 studies found a high prevalence of 
depression in the second (12.8%) and third (12.0%) trimesters. However, most of these studies 
were from HICs, with the exception of one Brazilian study. In addition, the included studies 
used screening tools (EPDS and BDI) with the risk of overestimating the prevalence (49). 
Antenatal depression in low-income countries (LICs), especially in Sub-Saharan Africa, have 
not been studied extensively. The available evidence suggests that the prevalence of antenatal 
depression in LMICs is comparable with that in HICs.  For instance, a review by Fisher reported 
a prevalence of 15.6% in LMICs (50), while a review which involved African women found 
11.3% of antenatal depression (51).   
In the few studies conducted in South Africa, Ethiopia and Zimbabwe, there appears to be 
variation in the prevalence of depression reported (14). For example, among 1062 pregnant 
women in Cape Town, South Africa, 39% of women screened positive for depression using the 
Edinburgh Postnatal Depression Scale (EPDS) (52), while in rural South Africa, almost half 
(47%, n=51/109) of pregnant women screened positive for depression on a major depression 
section of the structured clinical interview for DSM-IV diagnoses, with 15.7% reporting prior 
history of depression (23). Among an urban population of pregnant women in Kwa-Zulu Natal 
province, South Africa, 38.3% of depressed women reported having thoughts of self-harm in 
the preceding 7 days (53). Similarly, in a population-based survey in Ethiopia, 29.5% of the 
1311 pregnant women screened positive on PHQ9 (Bitew et al 2016). However, a low 
prevalence of antenatal depression (5.3%, n=23) was reported in Zimbabwe: 437 pregnant 
women completed the Shona Symptoms Questionnaire (SSQ), and only 73 (17%) met the 
criteria for psychological morbidity (24). The low prevalence might be due to the methodology 
that was applied. Clients were first screened using SSQ and those who screened positive were 
then referred to a psychiatrist for further evaluation. The Zimbabwean study is among the few 
studies in which clients were screened first then referred for clinical evaluation. Their 
prevalence is likely to reflect the true prevalence compared to studies in which the outcome 
measure was based on screening tools. 
Given that women (54), PLHIV (8) and pregnant women (50) are all at increased risk for 




2.2.1.1 Depression among HIV-positive pregnant women 
There is some research available that has investigated the prevalence and factors associated 
with depression among HIV-positive pregnant women specifically. These findings suggest that 
pregnant women living with HIV are at greater risk of experiencing symptoms of depression 
compared to pregnant women without HIV (6). In a recent systematic review of perinatal 
depression among HIV-infected women in Africa, only 2 studies used a diagnostic tool, while 
9 studies used screening tools in reporting the prevalence of depression. The mean prevalence 
of antenatal depression was reported to be 23.5% using a diagnostic tool, while the mean 
prevalence using screening tools was 43.5% (14). In KwaZulu-Natal, 99 (41%) of the total 224 
HIV-positive pregnant women screened positive for depression using EPDS (55). In a 
prospective cohort study in rural Uganda, the overall prevalence of depression was 38.9% 
(173/447) with a slightly higher prevalence during the antenatal period (42.7%, n=44/104) 
compared to the postpartum period (36.8%, n=111/303). The mean depressive symptom score 
for pregnant women was 1.29 (s=0.38) with >1.75 considered as possible depression (25).  
A few studies conducted in Africa reported conflicting results on the prevalence of antenatal 
depression in HIV-positive pregnant women compared with HIV-negative pregnant women. In 
the little available literature on antenatal depression, there are observed differences between 
studies. For example,  in KwaZulu-Natal, South Africa, 38.5% (149/387) of women in the 
antenatal period had an EPDS score of ³13 with a higher prevalence of depression among HIV-
positive women (42%, 43/104) compared to HIV-negative women (33%, 66/201). However, 
the prevalence was much higher (45%, 3/73) among women with unknown HIV status 
compared with HIV-negative women (53).  Another study from rural South Africa found no 
difference in the prevalence of antenatal depression in HIV-positive pregnant women (52.9%, 
n=27/51) compared to HIV-negative pregnant women (47.1%, n=24/51) (23). Notably, Rochat 
and colleagues (23) used DSM-IV diagnostic criteria, which are more accurate compared to the 
EPDS. These differences are probably due to the differences in the screening tool or diagnostic 
tool used, as discussed previously, as well as the timing of the depression screening. 
The reason for the high prevalence of depression amongst HIV-positive pregnant women could 
be that receiving a positive HIV result is shocking, especially to women who consider 
themselves not at risk of being infected with HIV.  Most of them are testing for the first time 
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as part of mandatory antenatal care. These women are worried about their own futures as well 
as the future of the unborn child (56). HIV-infected pregnant women in a Zambian study all 
believed that they were harming their unborn child (56). They were worried and anxious about 
what would happen to the unborn child, and expressed self-blame for exposing their unborn 
child to HIV. All of these reasons may compound the risk of developing depression during the 
antenatal period (57). Some HIV-infected pregnant women reported a loss of interest in life, 
and feeling guilty with recurring suicidal ideation (58). The majority (88.8%) of HIV-positive 
pregnant women in the Zambian study reported having thoughts of terminating their pregnancy 
(56).  
Although men may be encouraged to accompany their spouse to her first antenatal appointment 
and therefore also test for HIV, this does not always happen and the burden gets placed on 
women to disclose their status to their partners. The whole process of when and who to disclose 
the status to is stressful, considering the foreseeable consequences attached with status 
disclosure, and the stress may put HIV-positive pregnant women at a higher risk of suffering 
from depression (59).  
Furthermore, the pathogenesis of HIV itself can damage the brain, especially the subcortical 
area, and result in depression issues, and it can also predispose one to other medical conditions 
resulting in mood disturbances. Additionally, a number of HIV medications have side-effects 
that lead to depression (60). Although not common, some of the HIV/AIDS presenting 
symptoms may mimic depression symptoms, contributing to the high prevalence in this 
population (60).  
In Tanzania, there are four studies that have investigated the prevalence of antenatal depression 
among HIV-infected women (20,27,28,61), and only one study among them evaluated anxiety 
(61). All studies were conducted in Dar es Salaam, with the same study population, either as a 
secondary analysis or one-point prevalence within a randomised control trial to evaluate the 
effect of multivitamin supplementation in health-related quality of life among women living 
with HIV.  However, none of these studies looked at the factors associated with antenatal 
depression and anxiety in this population. 
Although these studies were conducted using data from the same randomised control trial 
(RCT), the prevalence of depression varied widely in different sub-populations of this study 
followed-up on over different time-periods, ranging from 7.7% to 73.4%. Kaaya conducted a 
secondary analysis of 99 HIV-positive pregnant women enrolled under the multivitamin 
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supplementation RCT to validate Hopkins Symptom Checklist-15 (HSCL-15). Pregnant 
women below 27 weeks of gestation were eligible for participation, and 7.7% were diagnosed 
with antenatal depression using SCID (61). However, a much higher prevalence was observed 
in other studies in the same population. For instance, the prevalence (74.3%) reported in 2013 
was almost double the prevalence (42.4%) reported in 2007 within a 5 year period, using the 
HSCL-15 (27,28). The difference in prevalence is probably due to the sample size and the tools 
which were used to diagnose or screen for depression. Three studies reported the prevalence of 
antenatal depression to be 42.4%, 42.7% and 73.4%, and enrolled 912, 891 and 188 participants 
respectively (20,27,28). In these studies, HSCL-8 was used to screen for probable depression 
with a cut-off score of >1.06. Kaaya and colleagues in 2002 used a diagnostic tool, not a 
screening tool, and also only 99 participants were included in the analysis (61), which might 
have contributed to the observed difference in the gestation of participants (7). Two of these 
studies included women with gestation below 27 weeks (27,61), one study enrolled only women 
between 20 to 40 weeks of gestation (28), and Antelman and colleagues did not specify the 
gestational age of their study participants (28). According to Sowa, of the 4 studies, none were 
judged as having good quality on a scale of 1 to 10; two of them had moderate quality, while 
the remaining two studies had poor quality. Therefore, it is important to investigate prevalence 
and factors associated with antenatal depression and anxiety in other parts of the country, with 
more focus on factors as none of the previous studies investigated factors. It is also important 
to investigate the prevalence of depression and anxiety outside clinical trial environments since 
all the previous studies in Tanzania were nested within an ongoing RCT.  
2.2.2 Anxiety 
Similar to depression, in clinical practice, the diagnosis of anxiety is also based on DSM-V 
criteria. However, in epidemiological studies, anxiety screening tools are more commonly used. 
Though validated and reliable, these screening tools differ in sensitivity and specificity. The 
screening tool used appears to influence the prevalence of anxiety reported in these studies. 
Some of the tools that were commonly used in the included studies are Depression Anxiety 
Stress Scale (62), Generalised Anxiety Disorders (63), and the HADS (40). More important to 
note is that the diagnosis of anxiety is challenging among people living with HIV. For example, 
if the timing of the diagnosis of anxiety is close to testing positive for HIV, it might just be a 
panic episode of the positive HIV test. Over the course of the HIV illness, it is difficult to tell 
whether anxiety is a side-effect of the medication, a HIV-related comorbid illness or a 
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psychological response to the stressors of the illness (64). All this should be taken into account  
when screening for anxiety among this population. 
Compared to the available literature investigating the prevalence of depression among the 
general population, PLHIV and pregnant women, studies investigating anxiety are more 
limited. Of the available literature, there is a wider variation in the reported prevalence of 
anxiety across regions. A few surveys reported a high prevalence of anxiety in HICs as 
compared to LICs. For example, according to the WMH Surveys, the prevalence of lifetime 
anxiety ranges between 4.8% and 31.0% in China and the United States respectively. In the 
African region, where data was only available from Nigeria and South Africa, the prevalence 
was 6.5% in Nigeria and 15.8% in South Africa (33). In the US, among people aged 13 years 
and above, the 12-month prevalence of anxiety was reported to be 31.6%. In this survey, the 
diagnosis of anxiety was made using DSM-IV (65). In a community-based cross-sectional 
survey in Malaysia, adults aged 18 years and above were screened using Generalised Anxiety 
Disorders. Of 1455 who completed the interview, 8.2% (n=119) had a score equal or greater 
than 8 cut-off point score for anxiety disorder (66). A national survey in Iran in 2015 found a 
much higher prevalence compared to that of Malaysia, Nigeria and South Africa. The 
prevalence of anxiety among adults was estimated to be 29.5%, similar to that reported in the 
US (67). 
The available literature suggests that certain groups are more at risk for anxiety. This includes 
1) women, 2) PLHIV, 3) and pregnant women. One systematic review of studies from both 
HICs and LICs found that anxiety is twice as high in women than in men. Importantly, all 
studies included in the review were representative and community-based, however, most of 
them used the CIDI in screening for anxiety (68). Similary, Kessler found a much higher 
prevalence of anxiety among women (37.3%) compared with men (25.6%) (65). Similar 
findings were reported in another national survey in the US. Both the lifetime and 12-month 
prevalence of anxiety among women were high compared with men. The 12-month prevalence 
was 22.7% versus 13.0%, while the lifetime prevalence was 33.3% versus 22.0% in women and 
men respectively (69). In Malaysia, anxiety symptoms were reported to be common among 
women as compared with men; men had a prevalence of 7.7% compared with 8.4% among 
women (66). However, Iranian men were more affected compared to women, with a prevalence 
of 33.8% and 25.1% respectively (67). 
PLHIV are at greater risk of anxiety compared to HIV-uninfected people. For example, of the 
491,796 clients in Britain who were followed-up with for a period of 14 years, 172 (3.1%) HIV-
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positive participants had anxiety symptoms while among the HIV-uninfected participants, 4161 
(1.7%) screened positive for anxiety symptoms (70). Other studies have reported non-
significant differences in the prevalence of anxiety between HIV-positive and negative 
participants. For example, in the USA, the adult prevalence of anxiety was reported to be around 
7%, with no significant difference between those who are HIV-infected and HIV-uninfected 
(71). Although not different from what was reported by Wixson et al  (66), and with no 
statistical significant difference, Morrison and colleagues found a prevalence range from 10.8% 
to 6.5% among women living with HIV and without HIV respectively (72).  
The literature on antenatal anxiety is limited, and suggests a high prevalence of antenatal 
anxiety. In one particular study, pregnant women were worried about giving birth and about 
too much weight gain during pregnancy (73). Of the 357 Chinese pregnant women screened 
using the HADS, more than half (54.0%) had high anxiety scores (74). The same findings were 
reported among women in Iceland. Participants were screened for anxiety using the anxiety 
subscale of the Depression Anxiety Stress Scale.  The prevalence was higher in the third 
trimester (50.9%) compared with the first trimester (47.4%) (75). Studies from Africa have 
suggested a much lower prevalence of antenatal anxiety compared with HICs. For example, in 
Egypt, of the 376 participants screened using HADS, 11.4% had symptoms suggestive of 
anxiety (76). A similar pattern of anxiety score was reported in Ivory Coast and Ghana. A total 
of 1030 Ivorian and Ghanaian pregnant women were screened using GAD-7, and of them 
11.4% Ghanian and 17.4% Ivorian were positive for anxiety symptoms (77). 
2.2.2.1 Anxiety among pregnant women living with HIV     
Since the prevalence of anxiety is high among women and PLHIV, it is likely that pregnant 
women living with HIV are more likely to experience anxiety symptoms compared to those 
who are uninfected.  Only a handful of studies have investigated the prevalence of anxiety 
among HIV-positive pregnant women specifically. These findings suggest that pregnant 
women living with HIV are at greater risk of experiencing symptoms of anxiety compared to 
pregnant women without HIV (6). A few studies have compared the prevalence rates of anxiety 
among pregnant women with and without HIV.  For instance, in the USA, a study on perinatal 
anxiety among 258 women with and without HIV reported significantly higher anxiety scores 
among HIV-positive women than HIV-negative women. Women were screened for anxiety 
using the State-Trait Anxiety Inventory (78). The difference was significant with a mean score 
of 37.1 (SD±13.8) for HIV-infected and 31.8 (SD±11.3) in HIV-uninfected women (78). 
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Another study in the US, which involved 45 HIV-positive pregnant women who received care 
at University of Miami/Jackson Memorial Medical Centre, reported a prevalence of 71.1% (79).  
2.2.3 Comorbidity of depression and anxiety in pregnant women living with HIV  
As discussed earlier, current evidence suggests that anxiety and depression are the most 
common mental illnesses. Whereas in some individuals the two conditions occur in isolation, 
more people present with the comorbidity of the two (80). Even with their coexistence, data on 
the comorbidity is sparse. Studying the distributions and factors associated with these disorders 
separately may underestimate the prevalence of mental health disorders, because they mask 
each other and patients with the two conditions may present with atypical signs and symptoms 
(80). Additionally, depression is associated with anxiety, whereby depressed participants have 
17 times higher odds of anxiety (56). 
Generally, it is estimated that more than half (50%) of patients diagnosed with depression also 
have anxiety symptoms (81). Similarly, more than half of patients visiting primary health care 
with depression also screen positive for generalised anxiety disorder (82). In addition, 12% of 
pregnant women in Cape Town, South Africa, screened positive for comorbid mental illnesses. 
In that population of pregnant women, the prevalence of comorbid anxiety and depression was 
52% (83). However, data on comorbid conditions among pregnant women living with HIV is 
scarce.  
2.3 Factors associated with antenatal depression and anxiety 
2.3.1 Factors associated with depression  
A systematic review of the risk factors of antenatal depression identified several independent 
predictors of depression. Some of the factors were pregnancy-related, such as unplanned 
pregnancy and pregnancy complications.  Social factors included a lack of partner support and 
a history of domestic violence (84). In addition to the mentioned factors, one review also 
reported relationship problems with a spouse and relationship problems with one’s in-laws (85). 
A systematic review by Bitew in Ethiopia linked depression with migration and substance abuse 
(86). Surprisingly, in the Ethiopian systematic review, socio-economic factors had no link to 
depression.   In Malaysia, they found that unmarried women with gestation below 20 weeks, 
and a history of mental illness and comorbid conditions were more likely to suffer from anxiety 
and depression. Women with a history of cesarean section had 3.14 higher odds of antenatal 
depression as compared to those without a history of cesarean section (7).  
 
 14 
Rochat and colleagues in South Africa identified factors such as unplanned current pregnancy, 
low household income and stigma/discrimination as factors associated with high antenatal 
depression scores (55). One strength of this South African cross-sectional study was the use of 
validated EPDS. Nevertheless, only women who currently tested positive for HIV, which has 
been reported to be associated with mental illness, were enrolled. Factors such as less education, 
low couple income, being unmarried, a prior history of poor pregnancy outcomes and an 
increased number of abortions were also identified as risk factors for depression among 
pregnant women (7,87,88).  
A number of factors have been found to be associated with perinatal depression among HIV-
infected women, ranging from individual to system factors. First, a positive HIV test result is a 
shocking life event and the worry of transmitting the virus to one’s unborn child is stressful, 
which adds to the risk of HIV-related depression among pregnant women (57). According to 
the new WHO recommendation of the PMTCT of HIV (Option B+) adopted by Tanzania in 
2013, all pregnant women who test positive must initiate triple ARV immediately, regardless 
of their CD4 count or WHO clinical stage (89). There is therefore limited time to understand 
their condition and accept the situation, and some are in denial while they have to protect the 
unborn child (90).  
Stigma and discrimination following HIV status disclosure remains of concern in many 
communities. For instance, in Tanzania, up to  32% of women are discriminated against and 
12% get divorced following their HIV status disclosure (91). In Uganda, increased time on 
ARV, viral suppression and better physical health were found to be associated with a lower 
mean score of depression (25).  In contrast to other studies in Uganda, never being married was 
found to be protective, while in other settings, not being in a relationship was found to be a risk 
factor for depression (79).  
Studies have also found that pregnant women with a history of post-traumatic stress disorder 
had a higher depression score compared to those with no history of post-traumatic stress 
disorder (79). In the US, among 45 HIV-positive pregnant women who screened positive for 
depression, 10% reported abuse during pregnancy which was significantly associated with 
depression (79). Kapetanovic and colleagues in Los Angeles, found that substance abuse during 
pregnancy or preconception was significantly associated with antenatal depression (92,93). Of 
the 328 HIV-positive pregnant women who were screened, 33 (10.1%) had a history of 
substance abuse during pregnancy and 16 (48.5%) screened positive for depression (92).  
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In Thailand, participants with an undisclosed HIV status and those who believed that their 
family would be ashamed of their HIV status were more likely to be depressed. Of the 129 
participants, 56% had disclosed their status to their partner only, 34% had disclosed to others, 
and 10% had not disclosed.  Almost all participants (77%) reported that their families would be 
ashamed of their HIV-positive status (59). Of the 129 participants,  46% of women screened 
positive for perinatal depression and HIV-related worry, and an undisclosed HIV status was 
associated with higher odds of HIV-related worry (59). Women with a higher perceived life 
stress, food insecurity, or social isolation were more likely to be depressed. For instance, in the 
US, the mean perceived stress score on the CES-D scale among 307 women was 10.4 
(SD±3.32). Women with higher levels of perceived stressors were more likely to be depressed 
(94), while a high CD4 count, good ARV adherence and higher perceived social support were 
reported to be protective factors (92). Positive partner support was also found to be associated 
with a low depressive symptoms score (94).  
2.3.2 Factors associated with anxiety 
As presented above, the prevalence of anxiety is high among the general population and many 
studies have identified factors contributing to this high prevalence. One global review of the 
risk factors of anxiety identified some of these factors as gender, age, culture, economic status, 
and urbanicity (95). In addition, job demand has been associatd with anxiety symptoms. In 
Dunedin, New Zealand, participants with excessive workload and time pressure had higher 
odds of anxiety compared to low job demands (96). In Malaysian adults, of the demographic 
characteristics, only marital status was significantly associated with anxiety symptoms.  
Depression was a significant factor associated with anxiety, whereby depressed participants 
had 17 times higher odds of anxiety. Other factors associated with anxiety were chronic illness 
such as cancer, domestic violence, a serious problem at work, an unhappy marriage, and 
intrinsic religiosity (66). Similarly, one cross-sectional study in Brazil found that anxiety was 
more common in participants with depression than those without depression (97). Interestingly, 
Marcus and colleague also reported that being female and having a low economic status were 
significant factors associated with anxiety (97). Witnessing traumatic events was also reported 
to be an independent predictor of anxiety. In South Africa, people who witnessed traumatic 
events had 78.0% increased odds of anxiety compared those who had not (98). 
Although few studies have investigated the factors associated with anxiety among pregnant 
women, they have identified several factors which are associated with anxiety among pregnant 
women.  Giving birth comes with a lot of concerns; one study has reported that pregnant women 
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are afraid about giving birth, especially for nulliparous women, and some are concerned about 
their body appearance post-delivery. Among Dutch pregnant women, anxiety symptoms were 
common among women who were pregnant for the first time, compared to those who had 
already been pregnant before (73), and women who were concerned about their body 
appearance post-delivery had high anxiety scores.   In Vancouver, Canada, women who were 
classified as having moderate and high risk of medical complications had high anxiety scores 
compared to those with low to no medical complications (22). Among Egyptian pregnant 
women, the only independent social factor associated with anxiety was their partner’s level of 
education; women married to illiterate men were more likely to experience anxiety (76). In 
addition, social support, self-esteem, and marital satisfaction were associated with anxiety 
symptoms among Chinese pregnant women (74). 
Among HIV-positive pregnant women, several factors contribute to the high prevalence of 
anxiety. Although literature is limited, some independent risk factors of anxiety have been 
identified. To start with, the trait of anxiety on its own is significantly associated with antenatal 
anxiety, while factors such as HIV status, perceived family support and history of child abuse 
among pregnant women receiving care in a Philadelphia hospital were found to be associated 
with antenatal anxiety (78). The time period of HIV diagnosis, comorbidities, and using first-
line ART medications were associated with anxiety symptoms. Women with depression also 
had higher levels of anxiety (99). HIV status disclosure and shame were strongly associated 
with anxiety symptoms. Not disclosing HIV status is associated with an increased risk of 
anxiety symptoms, as is having beliefs that your HIV status is a shame to your family (59).  
Although depression and comorbid anxiety might present with different signs or symptoms, the 
two conditions share common risk factors. Furthermore, the factors associated with depression 
and anxiety are the same factors that predispose someone to comorbid depression and anxiety. 
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Figure 1: Modified Stringer vicious cycle between HIV and depressive symptoms (13).   
2.4 Implications of Untreated Depression and Anxiety among Pregnant Women 
Despite antenatal depression being common, current literature on its impact is limited. Studies 
have found that antenatal depression not only carries a risk to the unborn child, but also that the 
mother experiences some consequences such as postnatal depression (22). Higher levels of 
antenatal depression were associated with poor child neurobehavioural outcomes (attention 
deficit disorder/hyperactivity) and poor cognitive functions, which were more common in boys 
than girls (22). Antenatal depression has also been found to impact on the nutritional status of 
children born to mothers with antenatal depression. In a community cohort study of 160 women 
with antenatal depression versus 160 healthy pregnant women, children born to mothers with 
antenatal depression were more likely to present with malnutrition (19). More specifically, 
children born to mothers with antenatal depression were 4.0 times more at risk of being under-
weight and 4.4 times more at risk of stunting as compared to those born to mothers without 
antenatal depression. Children born to mothers with antenatal depression were also at a higher 
risk of suffering from diarrhoea as compared to those born to mothers without antenatal 
depression (19).  
Several studies have associated antenatal depression with the development of postpartum 
depression and other psychiatric disorders (100). For instance, in Thailand, screening positive 
for depression during pregnancy was significantly associated with postpartum depression; 
women with a history of depression during pregnancy had 2.5 higher odds of postpartum 
depression (101). Among Turkish women, those with antenatal depression had 10 times higher 
odds of postpartum depression (102). Similarly,  Zambian women with antenatal depression 
HIV Depression & anxiety 
Poor perinatal outcomes 
e.g. HIV-infected infant 
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had 5.6 thime higher odds of postpartum depression as compared to those with no history of 
postpartum depression (103). 
Gaining further understanding of antenatal depression and anxiety among HIV-infected women 
not only affects the lives of the mother and the unborn child, but also the community at large. 
While there is a paucity of published data on the impact of antenatal anxiety among HIV-
infected women, the evidence on the impact of depression is compelling (13). Findings from a 
study in Tanzania showed that antenatal depression accelerates the rate of HIV disease 
progression to a more advanced HIV/AIDS WHO clinical stage, and is linked to a decline in 
CD4 count and increased risk of mortality (20). Two recent review articles reported poor ARV 
adherence among pregnant women with depression as compared to pregnant women without 
depression (13,104). In the US, depression was associated with poor ARV adherence, whereby, 
of the depressed women, none reported excellent (100%) ARV adherence as compared to 57% 
of non-depressed women in their third trimester. Only 22% (2/9) of the depressed women had 
achieved HIV RNA viral load <400 copies/mL at delivery compared with 71% (10/14) of non-
depressed women (105), which is a risk of MTCT of HIV. The poor ARV adherence not only 
increases the risk for vertical transmission of HIV but also the risk of developing ARV drug 
resistance (106). The resistant virus can be transmitted to the unborn child by vertical 
transmission and also to other people through sexual intercourse, limiting their future ARV 
options, especially in LMICs where ARV options are limited (107). Furthermore, pregnant 
women with depression are less likely to attend regular clinic visits for drug refill and pregnancy 
monitoring, contributing to poor adherence and increasing risk of vertical transmission of HIV. 
For instance, in the US, among 131 HIV-infected women with 146 pregnancies during the 
follow-up period, 4 of the children were infected with HIV and all of them were born to mothers 
who had no adequate antenatal care (108). Pregnant women with depression are also less likely 
to negotiate condom use. This puts them at risk of forward transmission of HIV to sexual 
partners, as well as to acquiring sexually transmitted infections, which may increase the risk of 
MTCT of HIV (109). For these reasons, it is important to investigate the prevalence and factors 
associated with antenatal depression and anxiety among pregnant women in order to identify 
women at risk and intervene at early stages.  
In Tanzania, to the best of our knowledge, there is no study that has investigated the factors 
associated with antenatal depression and anxiety among HIV-positive women. Thus, the 
objective of the present study is to determine the prevalence and factors associated with 
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depression and anxiety among HIV-infected pregnant women attending antenatal clinics in 




CHAPTER 3: METHODS 
 
3.0 Introduction  
This chapter covers the study design, study setting, sample size and sampling for the parent 
study, the data collection procedures for the parent study, the description of measurement tools 
used, data analysis, and ethical considerations. 
3.1 Study design 
In this study, we cross-sectionally analysed the baseline data from an ongoing hospital-based  
cohort study of HIV-positive pregnant women in the antenatal period.   
3.2 Study setting 
The parent cohort study was conducted in Moshi municipality and district council. These two 
districts are among the seven districts of the Kilimanjaro region (figure 2).  According to the 
2012 population census, the region had a population of 1,640,087 people, with 846,947 women 
and 793,947 men. The Moshi municipality population was 184,292, with 89,174 men and 
95,118 women. The Moshi district council population was 466,737 of which 225,767 were men 
and 240,970 women (110). The HIV testing among pregnant women, excluding those with 
known status, is 100% in Kilimanjaro (111). However, the region is among the bottom three 
with the percentage of women who get couples HIV testing during pregnancy (40%, versus a 
national target of 60%) (111). As per the national PMTCT guidelines, all pregnant women who 
are identified as HIV-positive start drugs for lifetime use. 
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Figure 2: The map of Tanzania showing the Moshi municipality and Moshi district.  
Source: http://dx.doi.org/10.4236/ojss.2014.413044 
Subjects were recruited at nine clinics in Moshi, including six from the Moshi municipality 
(Majengo, Masaranga, Pasua, Bondeni, St. Joseph, and KCMC) and three from the Moshi 
district (Himo, Faraja, and Cogi). These clinics were selected because of their high density of 
PMTCT clients. Additionally, women were enrolled from different levels of the health facilities 
in order to represent the structure of the health system in Tanzania, which is pyramidal in shape 
(fig. 3), with over 7000 operating health facilities (available at http://opendata.go.tz/dataset/list-
of-health-facilities-with-geographical-location). 
KCMC is among the four consultant hospitals in Tanzania, serving the northern zone of the 
country. St. Joseph is a district hospital serving urban Moshi. At both KCMC and St. Joseph, 
there are trained medical doctors who are able to diagnose and manage clients who screen 
positive for depression and/or anxiety.  Himo, Faraja, Pasua, Msaranga and Majengo are health 
centres, while Bondeni and Cogi are dispensaries (figure 3). At the health centre and dispensary, 
there are no medical doctors to care for people with mental illness; only trained, psychiatric 
nurses or counsellors are present. The nurses at these levels are allowed to diagnose and manage 
mild mental health conditions. The psychiatric nurses are supposed to refer serious cases to the 
facilities with expertise for further management. Stable clients are referred back to nurses to 
continue with monitoring. 
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Figure 3: The health system structure in Tanzania 
Tanzania is among the countries that are implementing WHO recommendations seeking to 
eliminate MTCT of HIV and keeping mothers alive (Option B+). Under Option B+ guidelines, 
all pregnant women who test positive for HIV are initiated on triple ARV medication regardless 
of their CD4 count. Women who initiate ARVs under Option B+ during pregnancy or 
breastfeeding are expected to continue with the drugs for life. PMTCT programmes are run by 
antenatal clinics in Tanzania and all health facilities in the country have an antenatal clinic. In 
addition to HIV testing and counselling, the clinics also provide a full package of maternal and 
child health services. The clinics are supposed to have a dedicated room for HIV pre- and post-
test counselling, and a dedicated HIV counsellor to provide test results and counsel women 
during their first clinic visit.  
3.3 Target Population 
Women were eligible to enroll in the cohort if they were pregnant, HIV-positive, and attended 
one of the nine selected antenatal clinics. Additional eligibility criteria were: 
• Age 18 years or above 
• Able to provide informed consent 
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• Diagnosed with HIV, either during the current pregnancy or prior  
• On ARV medication for at least four weeks prior to study entry  
• Second trimester or later in pregnancy 
3.4 Sample size estimation  
A sample size calculation was conducted to estimate the prevalence (P) of depression and 
anxiety amongst HIV-positive pregnant women with an error margin of ± 0.05 and with a 73.4% 
previous prevalence of antenatal depression among HIV-infected pregnant women in Dar es 
Salaam (27). 
n = Z2 1-α/2 P(1-P) = 1.962*0.734 (1-0.734) = 300 
             e2                        0.05*0.05                                    
where: 
 n = number to sample 
 Z2 = (1.96)2 for 95% confidence (α= 0.05)  
P = prevalence from previous study (73.4%)  
e = maximum tolerable error for the prevalence estimate (0.05) 
Although the minimum required sample size was 300, the parent study only enrolled 200 
pregnant women living with HIV. As per the parent study project timelines and funding, the 
team decided to close enrollment at the end of August 2017. A total of 200 participants were 
enrolled by this time, a sample which was determined to be enough to answer the parent study 
objectives. Using a sample of 200 women, the precision of the population estimate is affected, 
with 0.06 margin of error.  
3.5 Procedures 
The following procedures were followed to identify and enroll clients in the parent Option B+ 
study. One research nurse was assigned to each selected antenatal/PMTCT clinic to collect data. 
At the initiation of the study, clinic registers were reviewed to determine the number of HIV-
positive pregnant women currently enrolled at each clinic and the number of new clients from 
this group who enrolled each month. These reviews showed that there were about 10 to 30 HIV-
positive pregnant women enrolled in PMTCT care at each clinic at the time of study initiation, 
and 3 to 6 new patients enrolled each month. Since pregnant women are given one-month 
supplies of ARVs, they were expected to return to the clinic within a period of one month to 
get their medication refilled.  
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The initial screening for potential clients was done by the clinic nurses. All pregnant women 
living with HIV were informed of the study and asked if they were interested in meeting with 
the research nurse.  The clinic nurses referred interested clients to the research offices for further 
screening and possible enrollment (figure 4 below). Clinic providers were given a monthly or 
per-referral incentive (depending on their preference) to acknowledge the time and effort spent 
to identify and refer potential participants. 
The research nurses welcomed all women visiting the research office and provided a detailed 
description of the study, including the objectives and procedures of the study. Those who met 
eligibility criteria and were willing to participate were asked to sign an informed consent before 
the interview. Those who did not wish to participate were released from any study follow-up 
and proceeded with their routine clinic visits. Clients who were not eligible because they had 
not yet met the criteria of being in the second trimester of their pregnancy or of having begun 
ART at least 4 weeks previously provided their contact information and were scheduled for 
enrollment in their next clinic visit.  
The interviews were conducted in private study offices located within the study clinics. The 
assessments were conducted in Kiswahili using a structured paper questionnaire. The 
assessment took approximately 60 to 90 minutes. Participants were reimbursed for 
transportation costs with a flat rate of 5,000 Tanzania shillings (about $2.30) and were provided 
with soft drinks and light snacks during the interview. 
The three nurses were all registered nurses in Tanzania. At the outset of the research, the nurses 
were trained by the investigators for five days on the basic principles of research, research ethics 
and data collection. Throughout the study, they received additional, ongoing training and 
supervision in study-related issues and general research topics. 
The data collection tools were translated into Kiswahili and then back-translated into English 
by two independent translators. If there was a change in the context of some of the questions 
after back translation, a team of Swahili and English-speaking study staff sat together and 
reached consensus. When Swahili versions of the measures were already available from 
previous studies (e.g. the Edinburgh Postnatal Depression Scale as translated by Kumar and 
colleagues), these were reviewed and adapted (112). Before commencement of data collection, 
a pilot survey was conducted and the tool refined accordingly. 
The study nurses were trained in patient risk assessment, counselling and managing emotional 
distress. The nurses were also trained in the creation of an individualised safety plan for clients 
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at risk of distress and self-harm. The nurses offered to counsel those with high emotional 





















Figure 4: Parent study screening and enrollment flow chart  
3.6 Measures 
In addition to a number of socio-demographic questions (e.g. age, marital status, level of 
education, employment status, partner’s HIV status) and history of physical illness in the past 
one month, the following measures were used to collect data in the parent Option B+ study. 
Depression: Depression was measured using the Edinburgh Postnatal Depression Scale (EPDS) 
(42). The EPDS is a reliable and valid tool in measuring perinatal depression. Notably, the 
original EPDS had a sensitivity of 86% and specificity of 78% (42). It has been used frequently 
in measuring perinatal depression in Africa (113). The tool has not been validated in Tanzania, 
but there is a Swahili translated version previously used in Kenya, another Swahili speaking 
215 presented to ANC but 
were never referred for 
screening  
436 HIV-infected pregnant women 
attended ANC at the 9 study sites during 
the enrollment 
221 screened for study 
enrollment  
200 enrolled in the cohort 
21 screened but not enrolled 
Ø 8 declined to participate 
Ø 2 had mental impairment 
Ø 1<18 years old 
Ø 4 delivered before enrollment 
Ø 6 below second trimester 
163 not enrolled but eligible 
Ø 44 never initiated ART 
Ø 14 never returned to the 
clinic following diagnosis 




country, which was modified for use (112). However, following Swahili translation, the local 
EPDS (92) was not validated which means its precision in measuring depression is unclear. 
Consistent with the need for validation, evidence from one systematic review suggested that 
the use of the locally available versions of EPDS in screening for depression is questionable. 
According to this review, of the 14 available native language EPDS versions, none met the 
recommended validity of over 80% (114).   
The EPDS contains ten questions asking about feelings over the past 7 days. Each question has 
four possible responses, with a score of 0 to 3. For clarity, we modified question 7, 9 and 10 of 
the Swahili version of EPDS, then back-translated to English with content retained per the 
original English version. No question was deleted or added to the original version of EPDS; 
only unfamiliar terminology in the Tanzanian context was replaced. In addition to statements, 
we added alternative words to help participants understand the concept.  The maximum 
summed score is 30, with a score of 10 or higher indicating possible depression and a score of 
13 or higher indicating likely depression.  
Different studies in low- and lower-middle-income countries (LLMICs) have used a different 
cut-off point for screening antenatal depression (114). The choice for the cut-off is a trade-off 
process between sensitivity and specificity. At a lower cut-off point, many women screen 
positive but with a significant number of false positives; however, in a clinical setting and with 
HIV-positive pregnant women who are at high risk of depression, the positive predictive value 
is expected to be high, justifying the study choice of 10 as cut-off point. In addition, a number 
of locally validated versions of EPDS in LLMICs used 10 points cut-off with quite reasonable 
sensitivity and specificity. The sensitivities and specificities in these studies ranged from 81.5 
to 88.9% and 73.1 to 91.5% respectively (114). The sample alpha coefficient internal 
consistency score was 0.88.  
Anxiety: Anxiety was measured using the anxiety subscale of the Brief Symptom Index (BSI) 
(115). Although not validated in Tanzania, the tool has been validated in Kenya (116). There is 
no Swahili translated version and therefore, before the commencement of data collection in the 
parent study, the tool was translated from English to Swahili and then back-translated to 
English. The six-item anxiety subscale from BSI-18 was administered: 1. Nervousness or 
shakiness inside, 2. Feeling tense or keyed up, 3. Suddenly scared for no reason, 4. Spells of 
terror or panic, 5.  Feeling so restless you couldn’t sit still, and 6. Feeling fearful. Items had a 
5-point response: not at all=0, a little bit=1, moderately=2, quite a bit=3 and extremely=4. The 
final score is calculated by computing the average score of all items. Based on instrument norms 
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for a non-clinical, female population, the cut-off for evidence of signs or symptoms of anxiety 
is a mean score of 1.01 or higher (117).  
Pregnancy-related variables: The questions included in the survey were about gestational age, 
prior adverse pregnancy outcomes (miscarriage/abortion, stillbirth), mode of delivery in the 
previous pregnancies (normal, caesarian section, forceps or other methods), pregnancy status 
(planned or unplanned pregnancy) and number of living children.  These questions were 
adopted from the standard obstetric and gynecological history. Questions adapted from 
Guttmacher pregnancy attitude measure (GUTT) were used to assess the attitude about the 
current pregnancy. The questions include: Right before you become pregnant, did you plan to 
get pregnant? Right before you become pregnant, did you want to have a baby at any time? 
Would you say this pregnancy came too soon, at about the right time or later than you wanted? 
Right before you become pregnant, would you say that your partner wanted you to become 
pregnant? Are there times when you didn’t or don’t feel so good about being pregnant?  
A modified version of GUTT was adapted from Speizer and colleagues (118). Each question is 
scored 0-3, with a maximum total score of 24. The variable was evaluated in a continuous scale, 
with a higher score indicating a planned or wanted pregnancy. The internal consistency of this 
measure in the present study was 0.91. 
HIV-related variables: To assess HIV and mental health, women enrolled were asked about 
their HIV diagnosis, HIV care they are receiving, and if they had disclosed their HIV status. 
The questions asked included the following: the time of HIV diagnosis, their ART status, and 
their partner’s HIV status. To establish if women had disclosed their status to anyone or to a 
sexual partner, they were asked the following: Have you told anyone about your HIV status? 
Who have you told? How soon after learning your HIV status did you disclose your status to 
these specific people? Has your HIV status ever been revealed without your consent? 
Intimate partner violence variable:  The modified WHO intimate partner violence tool was used 
to assess for history of intimate partner violence. The tool has been validated and frequently 
used in LMICs (119,120), including among pregnant women (121). Questions asked about 
emotional abuse (“Has a spouse/partner ever insulted you or called you bad names?”), physical 
abuse (“Has partner/husband ever hit, slapped or hurt you physically in any other way?”), and 
sexual abuse (“As an adult, has someone ever forced you to have sex when you didn’t want 
to?”). Each question was assessed for both lifetime experience and recent experience in the past 
3 months. In addition to these three types of abuse, a question was added to ascertain whether 
 28 
the woman had experienced any sexual abuse in her childhood. The violence scores were 
dichotomised into yes or no, with a yes to any of the above questions being indicative of 
violence. 
Stigma-related variables: The questions on enacted stigma were adapted from the Holzemer 
stigma tool (122). The eleven questions used to assess stigma were adapted from the HIV 
stigma questionnaire. The HIV-related stigma questionnaire is a validated questionnaire; the 
data used for its validation was gathered from five Sub-Saharan African countries, including 
Tanzania. Women were asked to rate how often they experienced the following forms of HIV 
stigma in the past three months: 1) asked to leave because of a cough, 2) someone stopped being 
a friend, 3) called bad names, 4) made to eat alone, 5) insulted, 6) people avoided her, 7) people 
stopped visiting her, 8) people ended their relationships with her, 9) blamed for her HIV status, 
10) the ability to earn money was impacted, and 11) people gossiped about her. Each item has 
4 levels of responses, from never=0 to most of the time=3. The items were summed, with a 
minimum score of 0 and the maximum score of 63, with higher scores indicating more 
experiences of stigma. The stigma score is rated by adding each item score and then dividing 
by the maximum expected score.  
HIV shame: The HIV- and abuse-related shame inventory (HARSI) was used to measure 
shame. The original tool consists of three subscales: HIV-related shame, the impact of HIV-
related shame on behaviour, and sexual abuse-related shame (123). The current study adapted 
13 statements from the 14-item HIV-related shame subscale of the HARSI. The statements used 
were:  
1. It is hard to tell other people about my infection.  
2. I have failed to live up to my own expectations by getting HIV.  
3. When I tell others I have HIV, I expect them to think less of me.  
4. I put myself down for becoming HIV+.  
5. Being HIV+ makes me feel defective like there is something wrong with me.  
6. I am ashamed that I'm HIV+.  
7. When others find out I am HIV+, I expect them to reject me.  
8. I struggle with feeling worthless because I have HIV.  
9. I am ashamed of my HIV symptoms.  
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10. I hide my infection from others.  
11. I have an overpowering dread that my HIV status will be revealed to others.  
12. I accept myself as an HIV+ person.  
13. Having HIV makes me want to hide, disappear, or even die.  
Women were asked to indicate how true the statements were to them in the past month on a 5-
Likert scale. The Likert scale responses ranged from 0=not at all to 4=very much. The minimum 
score was 0 and the maximum score was 52. The sample alpha coefficient internal consistency 
score was 0.86.  
Food insecurity: The household food insecurity access scale was used to assess household food 
availability. The tool has been validated in different countries including Tanzania and translated 
into different languages (124). The study adapted four questions from the nine-item household 
food insecurity scale. The questions were: 1) In the past month, how often could you not feed 
your family?, 2) In the past month, how often were you hungry, but did not eat because you 
could not afford enough food?, 3) In the past month, how often did you or other adults in your 
household not eat for a whole day because there was not enough money for food?, and 4) In the 
past month, how often did you or other adults in your household cut the size of your meals 
because there was not enough money for food? Each item had 4 response options: 0=never, 
1=once or twice, 2=more than once or twice but not every day, and 3=every day. The scores 
were dichotomised into yes and no. ‘Never experienced food insecurity’ was no, while the rest 
were yes. 
Alcohol use: The modified (AUDIT-C) version of the 10 item AUDIT instrument was used. It 
has been validated in Africa (125) and contains 3 items which are used to screen alcohol abuse. 
The questions are: 1. How often do you have a drink containing alcohol?, 2. How many standard 
drinks containing alcohol do you have on a typical day?, and 3. How often do you have six or 
more drinks on one occasion? Each question has 5 choices, ranging from 0 to 4 points. In this 
study, alcohol use was dichotomised into alcohol drinker and non-drinker. 
Social support: The Duke-UNC Functional Social Support Questionnaire was used to measure 
social support (126). The tool has been validated in some LICs like Rwanda (127). It has not 
been validated in Tanzania, but has been used by some researchers in Tanzania to measure 
social support among HIV-positive clients (20). The tool contains 10 questions that participants 
were asked to respond to; 6 questions are about emotional (affectionate) support and 4 questions 
are about material support. The items are scored on a 4-point scale: 1=as much as I would like, 
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2=less than I would like, 3=much less than I would like, and 4=never.  Items were summed 
using median with its respective interquartile ranging. The sample alpha coefficient internal 
consistency score was 0.82.  
3.7 Data analysis 
Immediately after the completion of each interview, the research assistant checked the 
questionnaires for completeness before the participant left the room. Data were double entered 
into a template in REDCap by two independent data entry volunteers. Disagreements between 
the two entries were automatically identified by the research software, then reviewed and 
reconciled by a research statistician who referenced the original questionnaire and, if needed, 
sought additional clarification from the study nurses. The final, reconciled data were then 
exported to SPSS version 24 for analysis.  
The mental health outcomes were dichotomised to reflect elevated symptoms that reflect the 
disorder. Possible depression was defined as having a score on the EPDS of 10 and above. For 
incomplete EPDS, mean imputation was used to obtain total score if a participant answered at 
least 8 items. Probable anxiety was defined as having a score on the BSI of 1.01 and above. For 
BSI, no imputation was required for missing responses, with one women excluded because she 
had not responded to any BSI items. Women were identified as having comorbid conditions if 
they met the criteria for both probable anxiety and possible depression. Individuals who met 
criteria for any of the disorders were coded as Yes (1) and No (0) if the condition was absent. 
Descriptive statistics were used to summarise the demographic and socio-economic 
characteristics of study participants. Logistic regression models were developed to determine 
the factors associated with possible depression, probable anxiety and comorbidity of anxiety 
and depression among HIV-positive pregnant women. Logistic regression is a statistical method 
of analysis in which one or more exposures determine a binary outcome. The result shows the 
independent contribution of each variable on the odds ratio of the outcome. The confounders 
are modeled together to demonstrate the independent contribution to the outcome of interest 
(128). Three multivariate logistic regression models were developed, one for factors associated 
with possible depression, another one for probable anxiety, and the final model for comorbidity 
of possible depression and anxiety. To control for confounder and reduce the residual 
confounding effects, factors with a p-value of 0.15 or less in bivariate analysis were considered 
eligible for inclusion in the multivariate analysis. A much higher p-value (of up to 0.2) than the 
conversional 0.05 performs better in selecting variables for inclusion in a multivariate logistic 
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regression (129). Results are presented with odds ratios and their 95% confidence intervals. 
3.8 Ethical considerations 
Ethical approval for the study was provided by the University of Cape Town Human Research 
Ethics Committee. The parent study was approved by the ethical review boards of the 
Tanzanian National Institute for Medical Research and Kilimanjaro Christian Medical 
University. The permission to use data from the Option B+ project was obtained from the 
study’s principal investigators and co-investigators.  
Informed consent process: Eligible participants were asked to sign a form providing informed 
consent before their participation. The research assistant also gave a brief verbal description of 
the study and provided a paper copy of the informed consent information sheet. Participants 
who could not read or write were asked to provide a thumbprint and their consent was verified 
by the signature of an impartial witness of the participant’s choice. Participants were allowed 
and encouraged to ask any questions or seek clarification at any point in the research. Study 
staff reassured participants that their participation was entirely voluntary, that they were free to 
withdraw at any time, and that their withdrawal from participating would not affect their clinic 
standing or the care they receive.  
Confidentiality: Even though this study involved minimal risk of breaking participant 
confidentiality, multiple precautions were taken throughout the research process to maintain 
confidentiality and minimise the risk of stigma or unintended disclosure of participants’ HIV 
status. Interviews were typically held on the same day as participant’s regular clinic 
appointments to minimise risk of being identified as HIV-positive based on their study 
participation. Study offices were intentionally located in areas with limited access or visibility 
to other clinic patients, and offices were not labeled nor otherwise associated with an HIV study.  
Study questionnaires contained no participant identifiers. Documents containing identifying 
information, such as names or contact information (e.g. informed consent form), were securely 
stored separate from the study data and linked only by a unique identifier. All study data were 
kept in a locked cabinet at all times, except for when they were securely transported to the main 
study office. The participants’ information was only accessible by the research team and 
regulatory authority when applicable.  
To maintain confidentiality, in any data presentation, dissemination, and publications only the 
participants’ unique numbers were used instead of their identifiers. The consent to share results 
in this manner was included in the informed consent. 
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Risk: This study involved minimal additive risk to the participants, given that secondary data 
analysis was used from the parent Option B+ study. For the parent study, the researchers 
anticipated some emotional discomfort at discussing challenging topics, especially those 
associated with their positive HIV status. The parent Option B+ study identified a trained 
counsellor at each clinic to help women who needed additional support.  
Benefits: During the interview, participants were offered soft drinks and snacks. They also 
received 5,000 Tanzanian Shillings (equivalent to 2.5 US dollars) to compensate them for their 
travel. All participants were informed of the potential for the broader benefit to society by better 
understanding the challenges facing HIV-positive pregnant women and the likelihood that this 
information would inform future interventions in the region. 
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CHAPTER 4: RESULTS 
4.0 Introduction  
This chapter presents the study findings. The results are arranged by study objectives. The first 
part of the chapter covers the socio-demographic and clinical characteristics of study 
participants. This is followed by the prevalence of both possible depression and anxiety and the 
comorbidity of the two conditions. The last part of this chapter presents the factors associated 
with possible depression, anxiety and comorbid depression and anxiety. 
4.1 General characteristics of study participants  
A total of 208 pregnant women living with HIV were eligible for participation; 8 (3.8%) of 
them declined to participate. Of the 200 participants enrolled in this study, the median (IQR) 
age was 30 years (25-35). More than half of the participants had primary education only (n=113, 
56.5%), and about half were married (n=98, 49.0%). More than a quarter had no income 
generating activity (n=60, 30.0%), and 111 (55.5%) were working in informal sectors. About 
half of the participants knew their HIV status prior to the index pregnancy (n=106, 53.0%), 88 
(83.0%) of whom had initiated ARV prior to their current pregnancy. When asked whether they 
had disclosed their status to anyone, 159 (79.5%) had disclosed to at least one person and more 
than half (n=119, 70.0%) had disclosed specifically to their sexual partner. See Table 1 below 
for details on the general characteristics of participants. 
Table 1: General characteristics of study participants (n=200) 
Characteristics n % 
Demographic characteristics    
Clinic   
   KCMC referral hospital  51 25.5 
   Pasua health center  61 30.5 
   Majengo health center  31 15.5 
   St. Joseph district hospital  21 10.5 
   Himo OPD 18 9.0 
   Others 13 6.5 
Median(IQR) age in years  30 (25 – 35) 
Education level attained   
   No formal education 4 2.0 
   Any primary education 113 56.5 
   Any secondary education 70 35.0 
   Any college 13 6.5 
Marital status   
   Married 98 49.0 
   In a relationship 72 36.0 
   Single 21 10.5 
   Separated/Divorced 9 4.5 
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Polygamous relationship   
   Yes 36 18.0 
    No 164 82.0 
Income-earning activities   
   None 60 30.0 
   Informal activities 111 55.5 
   Formal employment 29 14.5 
Partner’s income-earning activities   
   None 2 1.4 
   Informal activities 88 62.0 
   Formal employment 29 20.4 
   Not in a relationship 22 15.5 
   Missing   1   0.7 
Drinks alcohol   
   Yes 54 27.0 
   No 146 73.0 
Pregnancy characteristics    
First pregnancy   
   Yes 44 22.0 
   No 156 78.0 
Gestational age mean (±SD) 28.4 (±5.6) 
Prior pregnancy outcome (n=156)   
   No problems 85 54.5 
   Negative outcomes 71 45.5 
Negative outcomes (n=71)   
   Abortion 7 9.9 
   Miscarriage  32 45.1 
   Still birth 12 16.9 
   HIV+ child 11 15.5 
   Death of a child 23 32.4 
HIV-related characteristics    
HIV diagnosis   
    New diagnosis 94 47.0 
    Established diagnosis 106 53.0 
Used ARVs before this pregnancy (n=106)   
   Yes 88 83.0 
   No 18 17.0 
Partner HIV status   
   HIV-negative 44 22.0 
   HIV-positive 61 30.5 
   Unknown 95 47.5 
Any HIV status disclosure   
   Yes 159 79.5 
   No 41 20.5 
Disclosed to partner (n=170)   
   No 51 30.0 
   Yes 119 70.0 
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4.2 Prevalence of possible depression and anxiety  
Among the 200 women enrolled, 50 (25.0%) women met the cut-off score for possible 
depression. Twenty-eight (14.1%) participants reported thoughts of self-harm, 8 (4.0%) of 
whom had these thoughts quite often. Of the 200 women screened for anxiety, 49 (24.6%) met 
the cut-off score for probable anxiety disorder.  
The prevalence of comorbid anxiety and depression was 18.1% (n=36). The majority (72%) of 
women who screened positive for possible depression also had anxiety. Table 2 below gives 
details on the comorbidity of anxiety and depression.  
 
Table 2: Prevalence of Comorbidity of Anxiety and Depression (n=199) 
 Depression status   
Anxiety status*  
No possible 
depression  
Possible depression Total 
No probable anxiety  136(90.7%) 14(9.3%) 150(75.5%) 
Probable anxiety  13(26.5%) 36(73.5%) 49(24.5%) 
Total 149(74.9%) 50(25.1%) 199 
*One participant did not complete the anxiety screening instrument (BSI) 
 
4.3 Factors associated with possible depression  
In bivariate analysis (Table 3), being a single woman, food insecurity, violence, social support, 
HIV shame, enacted stigma and attitude about pregnancy were significantly associated with 
possible depression. Single women had 3.2 times higher odds of depression compared to 
married women  (cOR=3.2, 95% CI=1.4 – 7.3). Women with a history of experiencing violence 
had 2.6 times higher odds of possible depression as compared to women who had never 
experienced violence in their life (cOR=2.6 95%CI=1.3 – 5.0). Women who reported food 
insecurity had 4.1 times higher odds of depression compared to those who had no food 
insecurity (cOR=4.1, 95% CI= 2.1 – 8.0). Furthermore, attitude about the current pregnancy 
was significantly associated with the odds of possible depression, where a unit increase in 
positive attitude about the current pregnancy was associated with a 10.0% decrease in possible 
depression (cOR= 0.9, 95% CI = 0.9 – 1.0). Women with perceived available social support 
had lower odds of possible depression; as perceived social support score increased, the odds of 
possible depression decreased by 10% (cOR=0.9 95% CI=0.9 – 1.0).  Women who had higher 
scores of HIV-related shame had higher odds of possible depression, where a unit increase in 
the HIV-related shame score was associated with a 1.2 increase in the odds of possible 
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depression (cOR=1.2, 95% CI=1.1–1.3). Similarly, increases in enacted stigma score among 
women were associated with a 1.3 increase in the odds of possible depression. Table 3 below 
provides the details on the factors associated with depression. 
In a multivariate logistic regression model (Table 3), three factors remained significantly 
associated with depression after controlling potential confounders. Women who were single 
had 4.1 times higher odds of possible depression compared with women who were married or 
in a relationship (aOR=4.1, 95% CI=1.2–14.6). Women who reported food insecurity had 2.6 
times higher odds of possible depression compared with those without food insecurity 
(aOR=2.6, 95% CI=1.0 – 6.6). Women with a higher score on HIV shame also had higher odds 
of depression; with each unit increase in HIV shame score, the odds of depression increased by 
1.2 (aOR=1.2, 95% CI=1.1 – 1.3).  
Table 3: Bivariate and multivariate analysis of factors associated with possible depression among 
pregnant women living with HIV (n=200) 















      
Primary 83(70.9) 34 (29.1) 1.7(0.9-3.4) 0.118 1.6(0.6-4.1) 0.330 
Secondary and 
above  
67 (80.7) 16 (19.3)     
Marital status       
Married 134 (75.8) 36 (24.2)     






      
Yes 26 (72.2) 10 (27.8) 1.6(0.7-3.7) 0.278   
No 108 (80.6) 26 (19.4)     
Income-earning 
activities 
      
None 43 (71.7) 17 (23.8) 1.2(0.6-2.5) 0.477   
Informal/Formal  107 (76.4) 33 (23.6)     
First pregnancy       
Yes 34 (77.3) 10 (22.7)     
No 116 (74.4) 40 (25.6) 1.2(0.5-2.6) 0.694   
Prior pregnancy 
outcome (n=156)  
      
No problems 66 (77.6) 19 (22.4)     
Negative outcomes 50 (70.4) 21 (29.6) 1.5(0.7-3.0) 0.305   
HIV diagnosis        
New diagnosis 71 (75.5) 23 (24.5)     
Established 
diagnosis 
79 (74.5) 27 (25.5) 1.0(0.5-2.0) 0.870   




102 (73.4) 37 (26.6) 1.3(0.6-2.7) 0.426   
HIV-positive 48 (78.7) 13 (21.3)     
Disclosure to 
anyone 
      
No 34 (82.9) 7 (17.1) 0.5(0.2-1.3) 0.193   
Yes 116 (73.0) 43 (27.0)     
Disclosure to 
partner (n=170) 
      
No 43 (84.3) 8 (15.7) 0.6(0.2-1.4) 0.255   
Yes 91 (76.5) 28 (23.5)     
Food Insecurity 
(FHI) 
      
Never 112 (84.2) 21 (15.8)     
Sometimes  38 (56.7) 29 (43.3) 4.1(2.1-8.0) <0.001 2.5(1.0-6.6) 0.054 
Ever experienced 
violence 
      
No 106 (81.5) 24 (18.5)     
Yes 44 (62.9) 26 (37.1) 2.6(1.3-5.0) 0.004 1.5(0.6-3.8) 0.354 
Drink alcohol       
No 111 (76.0) 35 (24.0)     













Age in years  30 (26-35) 30 (24-35)  1.0(0.9-1.0) 0.532 1.0(0.9-1.1) 0.892 
Social support  30(24-36) 26.5(23-30) 0.9(0.9-1.0) 0.001 1.0(0.9-1.0) 0.312 
HIV Shame 15(10.7-20) 29(22.7-35) 1.2(1.1-1.3) <0.001 1.2(1.1-1.3) <0.001 
Enacted stigma 0 (0 – 0) 0 (0 – 2) 1.3(1.0-1.5) 0.014 1.0(0.9-1.2) 0.592 
Attitude about 
pregnancy 
16(13-19.5) 14(9.7 – 16) 0.9(0.9-1.0) 0.007 0.9(0.8-1.0) 0.119 
cOR, crude odds ratio, aOR, adjusted odds ratio  
Adjusted for social support, enacted stigma, attitude about pregnancy, HIV shame, level of education, 
marital status, food insecurity and violence  
 
4.4 Factors associated with probable anxiety 
In bivariate analysis (Table 4), factors that were significantly associated with probable anxiety 
were marital status, food insecurity, HIV shame, experience of violence, and enacted stigma. 
Women who reported food insecurity had 2.4 times higher odds of probable anxiety compared 
with those with no food insecurity (cOR=2.4, 95% CI=1.2 – 4.6).  Women who reported 
lifetime violence of any kind had 3.0 times higher odds of probable anxiety compared to those 
who had never experienced violence (cOR=3.0, 95% CI=1.6 – 5.9). Furthermore, single women 
had 2.8 times higher odds of probable anxiety compared with women who were married 
(cOR=2.8, 95% CI=1.2 – 6.4). More enacted stigma was associated with higher odds of anxiety; 
a unit increase in stigma score was associated with 1.3 times increase in the odds of probable 
anxiety (cOR=1.3, 95% CI=1.1 – 1.6). Women who were ashamed of their HIV status had 
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higher odds of probable anxiety. Per unit increase in shame score was associated with 1.1 times 
higher odds of anxiety (cOR=1.1, 95% CI=1.1 – 1.2). 
In a multivariate logistic regression model (Table 4), HIV shame and lifetime experience of 
violence of any kind remained significantly associated with probable anxiety after controlling 
for potential confounders. Women with a higher score of HIV shame had higher odds of 
probable anxiety; a unit increase in HIV shame score among women was associated with 1.1 
times increased odds of probable anxiety (aOR=1.1, 95% CI=1.1 – 1.2). Women who reported 
a history of lifetime violence of any kind had 2.3 times higher odds of probable anxiety 
compared to those who had never experienced violence (cOR=2.3, 95% CI=1.0 – 5.1). 
 
Table 4: Bivariate and multivariate analysis of factors associated with probable anxiety among 
pregnant women living with HIV (n=199) 





















      
 
Primary/N
o formal  
84 (71.8) 33 (28.2) 1.6 (0.8 – 3.2) 0.163 1.5(0.6-3.6) 0.323 
   
Secondary 
and above  
66 (80.5) 16 (19.5)     
Marital status       
Married 133 (78.7) 36 (21.3)     
Single 17 (56.7) 13 (43.3) 2.8 (1.2–6.4) 0.012 2.3(0.7-7.2) 0.139 
Polygamous 
relationship  
      
   Yes 30 (83.3) 6 (16.7) 0.7 (0.3 –1.8) 0.446   
    No 103 (77.4) 30 (22.6)     
Income-earning 
activities 
      
None 43 (71.7) 17 (28.3) 1.3 (0.7 –2.6) 0.426   
Informal/Formal  107 (77.0) 32 (23.0)     
First pregnancy       
   Yes 30 (69.8) 13 (30.2) 1.4 (0.7 –3.0) 0.336   
   No 120 (76.9) 36 (23.1)     
Prior pregnancy 
outcome (n=156)  
      
   No problems 68 (80.0) 17 (20.0)     
     Negative 
outcomes 
52 (73.2) 19 (26.8) 1.4 (0.7-3.1) 0.320   
HIV diagnosis        
     New diagnosis 71 (76.3) 22 (23.7)     
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     Established 
diagnosis 
79 (74.5) 27 (25.5) 1.1 (0.6 –2.1) 0.767   
Partner recent test        
    HIV-
negative/Unknown  
101 (73.2) 37 (26.8) 1.5 (0.7-3.1) 0.283   
    HIV-positive  49 (80.3) 12 (19.7)     
Disclosure to 
anyone 
      
     No 32 (78.0) 9 (22.0)     
     Yes 118(74.7) 40 (25.3) 1.2 (0.5 –2.7) 0.748   
Disclosure to 
partner (n=169) 
      
     No 40 (78.4) 11 (21.6) 1.0 (0.5 –2.3) 0.956   
     Yes 93 (78.8) 25 (21.2)     
Food Insecurity 
(FHI) 
      
Never 107 (81.1) 25 (18.9)     
Sometimes 43 (64.2) 24 (35.8) 2.4 (1.2 –4.6) 0.010 1.3(0.5-3.0) 0.599 
Ever experienced 
violence 
      
No 107 (82.9) 22 (17.1)     













Age in years  30.5 (26-35) 28(24-35) 1.0 (0.9-1.0) 0.153 1.0(0.9-1.0) 0.445 
Social 
support(PAS) 
29(24 - 34) 27(23-
31.5) 





1.1 (1.1 -1.2) <0.001 1.1(1.1-1.2) <0.00
1 





0.9 (0.9 –1.0) 0.081 0.9 (0.9-
1.0) 
0.203 
crude odds ratio, cOR; adjusted odds ratio, aOR 
adjusted for level of education, marital status, perceived availability of social support, HIV shame, 
enacted stigma and attitude about current pregnancy  
One participant did not complete anxiety screening instrument (BSI) 
 
4.5 Factors associated with comorbid depression and anxiety 
In bivariate analysis (Table 5), marital status, experience of violence, food insecurity, HIV 
shame, attitude about pregnancy, enacted stigma and social support were significantly 
associated with a participant having comorbid depression and anxiety. In this cohort of women 
living with HIV, single women had 3.3 times higher odds of comorbidity compared to married 
women (cOR=3.3, 05% CI=1.4 – 7.8). Participants with food insecurity had 3.6 times higher 
odds of comorbidity compared to those who never experienced food insecurity (cOR=3.6, 95% 
CI=1.7 – 7.5). Women with a history of experiencing violence of any kind had 4.4 times higher 
odds of comorbidity as compared to women with no history of experiencing violence (cOR=4.4, 
95% CI=2.0 – 9.3). Women with perceived lower social support had higher odds of anxiety and 
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depression; for every one unit increase in social support score, the odds of comorbidity 
decreased by 10% (cOR=0.9, 95% CI= 0.9 – 1.0). Attitude about current pregnancy had a 
significant association with the odds of comorbidity. Each unit increase in the positive attitude 
about current pregnancy was associated with a 10% decrease in comorbidity (cOR= 0.9, 95% 
CI = 0.8 – 1.0). Women who reported experiencing stigma had higher odds of comorbidity; as 
stigma scores increased, the odds of comorbidity increased by 1.3 (cOR=1.3, 95%CI=1.1 – 
1.6). Women who scored higher on HIV shame also had higher odds of comorbidity; for every 
one unit increase in HIV shame score, the odds of comorbidity increased by 1.2 (cOR=1.2, 95% 
CI=1.1 – 1.2). 
In a multivariate logistic regression model (Table 5), the experience of violence and HIV shame 
were found to be significantly associated with comorbidity among pregnant women living with 
HIV. After adjusting for potential confounders, women who had ever experienced violence had 
3.6 times higher odds of comorbidity compared with no history of experiencing violence 
(aOR=3.6, 95% CI=1.3 – 9.9). Women who had higher scores of HIV shame also had higher 
odds of comorbidity; for each unit increase in HIV shame score, the odds of comorbidity 
increased by 1.2 (aOR=1.2, 95% CI=1.1 - 1.3).  
Table 5: Bivariate and multivariate analysis of factors associated with comorbidity of depression and 
anxiety (n=199) 
 Probable Anxiety and 
possible Depression  

















      
   Primary/No 
formal  
92 (78.6)     25 (21.4) 1.7(0.8 – 3.8) 0.155 1.6(0.5-5.0) 0.365 
   
Secondary/Higher 
education  
73 (86.6) 11 (13.4)     
Marital status       
   Married 144 (85.2) 25 (14.8)     





      
   Yes 114 (85.7) 19 (14.3) 1.1(0.4 – 2.9) 0.768   
   No 30 (83.3) 6 (16.7)     
Income-earning 
activities 
      
   None 46 (76.7) 14 (23.3) 1.6(0.8 – 3.4) 0.209   
   Informal/Formal  117 (84.2)      22(15.8)     
First pregnancy       
   No 129 (82.7) 27(17.3)     
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   Yes 34 (79.1) 9 (20.9) 1.3 (0.5-2.9) 0.585   
Prior pregnancy 
outcome (n=157)  
      
   No problems 72 (84.7) 13 (15.3)     
   Negative 
outcomes 
57 (80.3) 14 (19.7) 1.4 (0.6-3.1) 0.468   
HIV diagnosis        
   New diagnosis 78 (83.9) 15 (16.1)     
   Established 
diagnosis 
85 (80.2) 21 (19.8) 1.3(0.6 – 2.7) 0.501   
Partner recent test        
   HIV-
negative/Unknown  
110 (79.7) 28 (20.3) 1.7(0.7-3.9) 0.229   
   HIV-positive  53 (86.9) 8 (13.1)     
Disclosure to 
anyone 
      
   No 36 (87.8) 5 (12.2) 0.6(0.2 – 1.6) 0.276   
   Yes 127 (80.4) 31 (19.6)     
Disclosure to 
partner (n=169) 
      
   No 44 (86.3) 7 (13.7) 0.9(0.3 – 2.3) 0.787   
   Yes 100 (84.7) 18 (15.3)     
Food Insecurity 
(FHI) 
      
   Never      117 (88.6) 15 (11.4)     
   Sometimes 46 (68.7) 21 (31.3) 3.6 (1.7-7.5) 0.001 1.6(0.5-4.7) 0.395 
Ever experienced 
violence 
      
  No 116 (89.9) 13 (10.1)     















Age 30 (26-35) 28(23-35) 0.9(0.9 – 1.0)  1.0(0.9-1.1) 0.575 
Social 
support(PAS) 
30 (24-35) 26(22.2-29) 0.9(0.9 – 1.0) 0.004 1.0(0.9-1.1) 0.574 
HIV Shame 
(HARSIH) 









16(12.6-19) 14(9 – 16.7) 0.9(0.8 – 1.0) 0.010 0.9(0.8-1.0) 0.077 
cOR, crude odds ratio; aOR, adjusted odds ratio, CI, confidence interval 
adjusted for marital status, violence, food insecurity, attitude about current pregnancy, enacted stigma, 





CHAPTER 5: DISCUSSION 
5.0 Introduction 
The purpose of this chapter is to discuss the findings that were presented in Chapter 4. It will 
start with a discussion of the study’s main findings concerning the prevalence and factors 
associated with possible depression, probable anxiety disorder and the comorbidity of anxiety 
and depression. Thereafter, limitations will be addressed. The chapter will conclude with 
implications for practice, training and policy development, as well as offering 
recommendations for future studies. 
5.1 General discussion  
The main results of this study are that: 1) compared to previous studies, a low prevalence of 
possible depression was reported among participants (25%) and was associated with marital 
status, food insecurity, and HIV shame; 2) symptoms of anxiety were common (24.6%) and 
were associated with HIV shame and lifetime experience of violence; and 3) a high rate of 
comorbidity was reported by participants, with 18.1% meeting criteria for both possible 
depression and probable anxiety. HIV shame and lifetime experience of violence were found 
to be significantly associated with comorbid depression and anxiety.  
Prevalence and risk factors associated with possible depression 
In the present study, one out of every four pregnant women with HIV had possible depression. 
Although these findings are comparable to the US prevalence of 22% (92), compared to studies 
conducted in other African countries and other studies in Tanzania, this prevalence is low. For 
example, in Uganda and South Africa, depression rates of 42.7% and 41.0% have been reported, 
respectively (25,55). Similarly, in Dar es Salaam, the prevalence of antenatal depression among 
women living with HIV was reported to be about twice (42.4%) or three times (74.3%) that of 
the prevalence in Moshi (27,28). 
There are a number of explanations that may account for the different rates of depression 
reported in the present study compared to the available literature in other African countries. 
Firstly, there are cultural and social-behavioural differences between Dar es Salaam and Moshi 
that might have contributed to the observed difference (130). For example, in Moshi, there is a 
cultural practice of travelling to visit the in-laws during pregnancy or after giving birth. At their 
in-laws, they are released from their duties and economic hardships. In Dar es Salaam, the 
opposite is the norm, where the in-laws travel from the village to visit with the new family, who 
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often is responsible for hosting their in-laws. Research suggests that the family, including in-
law social support, has been shown to be associated with low risk of stress and fewer odds of 
depression in the antenatal and postnatal period (131).  
A second possible explanation for the varying rates of depression is the difference in study 
designs. These might have contributed to the observed difference in mental health prevalence. 
The current study is cross-sectional, whereas in the previous studies women were recruited and 
then followed up on. They were followed up on from study entry, and information on their 
mental health was collected periodically. During the follow-up, some women may have started 
to face some HIV-related challenges as they were starting to adapt to their status, including the 
new reality of life and coping with life changes. In the present study, about half of the women 
were newly diagnosed and enrolled in this study four weeks post-diagnosis, and either mental 
health symptoms may not have developed or participants may not have felt comfortable 
admitting to the symptoms.  
Finally, the screening tools used to detect depression vary across studies. In the previous studies 
conducted in Tanzania, HSCL was used to screen for depression, while this study used EPDS 
(28). Similarly, Kaida in Uganda also used the modified HSCL to screen for antenatal 
depression (25). Different depression screening tools might have contributed to the observed 
difference in the prevalence. 
Although the prevalence of antenatal depression was lower than in previous studies, the 
reported prevalence of depression still warrants concern for the mental health of pregnant 
women living with HIV in Tanzania. The Tanzanian national PMTCT guidelines highlight the 
importance of managing mental health disorders among women living with HIV. However, 
there are no strategies in place to screen and manage those diagnosed with depressive symptoms 
(132). As a result, many of these women with possible depression will go undetected. The 
implications of not providing mental health treatment for pregnant women living with HIV in 
Tanzania are many. Untreated depression could progress to severe or chronic depression. In its 
early/less severe stages, depression may be easier to manage. More severe depression requires 
well-trained health professionals who are not readily available in most of the African settings 
(133). Additionally, without adequate support and help in dealing with their depression, women 
with HIV may be less likely to adhere to taking their medication and more likely to miss their 
clinic schedules (134). All of these pose challenges to the elimination of MTCT of HIV (132), 
and the UNAIDS targets set to help end the HIV epidemic by the year 2030 (the 90-90-90 
target) (135).  
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The prevalence of possible depression reported here was associated with several health factors 
including food insecurity, HIV shame, and marital status. Similarly, in Uganda and the US, 
food insecurity was significantly associated with depression (94,136). Furthermore, one study 
in South Africa reported that 29% of participants at a primary level clinic did not have enough 
food for their families and this was associated with mental illnesses (137). A proportion of 
pregnant women enrolled in the current study had a low socio-economic status and did not have 
enough food to feed their families. Several studies have demonstrated the link between low 
socio-economic status among PLHIV and mental illnesses (25,137,138). The findings here 
which show a relationship between poverty and mental health are supported by a systematic 
review by Lund and colleague, which found an association between mental illnesses and 
poverty (138). Moreover, PLHIV are advised by their physicians, as per HIV/AIDS treatment 
guidelines, to eat a balanced diet, and some of the ARV medications increase appetite or are 
supposed to be taken with food (137,138,139). With this in mind, it is not surprising that 
pregnant women who experience food shortages have higher rates of depression. The findings 
raise concerns about social disparities among PLHIV, and show that interventions should not 
only focus on the physical health but should also address the social aspect of clients. 
Women in the sample with high HIV shame scores had higher odds of depressive symptoms. 
Many PLHIV feel ashamed of their status and also feel that they have let their families down 
(142). Additionally, many believe that having HIV is a punishment for their behaviour or the 
behaviour of their partner (142,143). Such feelings and blame for their behaviour may increase 
the risk of depression.  In some cases, the shame experienced among these women could be due 
to the stigma that still exists. Several other previous studies have reported a similar association 
(59,134). Shame is an important aspect to address, because it may lead women to avoid clinic 
appointments. To address the issue of HIV-related shame, the Tanzanian national HIV 
counselling guidelines have incorporated HIV-related shame. The guidelines advocate for 
identifying clients who are ashamed of their status, counselling them, and providing them with 
support on how to overcome the feeling (89). A major concern is the workload of staff at these 
clinics, which makes it difficult to implement the PMTCT guideline of addressing HIV-related 
shame, especially among newly diagnosed clients. More efforts are still needed to address HIV-
related shame, which impacts women’s well-being and potentially undermines the efforts of 
the health system. 
Single women were at higher risk of depression compared to married women. The results are 
consistent with previous studies (79).  Being single and pregnant might not be a women's 
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choice, but rather may be a result of unplanned pregnancies, divorce or being abandoned, 
among others. The circumstances resulting in a pregnant woman being single in the Tanzanian 
context might contribute to depression. Not having a partner to comfort them at the time needed 
undermines social support and contributes to the risk of depression. Contrary to our findings, 
in Uganda, being single was found to be protective (25). The Ugandan finding is in contrast to 
the current body of knowledge, which suggests that marriage offers protective benefit for 
mental illnesses. Kaida and colleagues acknowledged the inconsistency but offered no 
explanation as to why there was a difference. 
Prevalence and risk factors associated with probable anxiety 
Similar to prevalence rates of depression reported in the present study, 24.6% of women 
screened positive for anxiety symptoms. As mentioned in Chapter 2, there are limited studies 
that have investigated the prevalence of anxiety in this population. Of the few available studies 
in the literature, there are some variations in the prevalence of anxiety. For example, one study 
in the US reported a much higher prevalence (71.1%) compared to what we found (79). 
However, that study had a sample size of 45. The sample size, design, anxiety measure, and the 
difference in the cultural context of mental illness might have contributed to the observed 
difference. In Tanzania, there is a paucity of data on the prevalence of anxiety among pregnant 
women living with HIV. Nonetheless, our findings are cause for concern. 
When not treated at its early stages, pregnant women with mild symptoms of anxiety may 
progress to severe symptoms. Women with a severe form of anxiety disorder are at increased 
risk of depression, substance abuse and suicidality (83). In the context of PMTCT, these women 
are less likely to adhere to their clinic appointments including taking their ARVs (132). In so 
doing, they are at greater risk for transmitting the virus to their unborn or breastfeeding infants. 
Maternal anxiety also introduces risks for poor perinatal outcomes such as intrauterine growth 
restriction, premature birth, and low birth weight, as well as impacts on the mental health of the 
baby (22). For example, one systematic review showed that anxious women tend to have 
children with mental health disorders, especially attention deficit disorder (22). Although the 
world has recorded a lot of advancements and achievements in the management of HIV, 
especially in the area of PMTCT, there is less focus on mental illnesses such as anxiety, 
especially in LIC. Even in the new WHO guidelines on PMTCT (Option B+), which advocate 
for keeping mothers alive (132), the focus is more on the physical health. The mental health of 
women is put aside, which is a drawback to achieving the target of keeping mothers alive. 
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Meeting this WHO target will require incorporating the mental health component, including 
anxiety, into routine PMTCT care. 
In this population of pregnant women living with HIV, anxiety was associated with HIV-related 
shame and lifetime experience of violence. Pregnant women who had greater HIV shame had 
higher odds of anxiety. One of the strategies for coping with a shameful event in life is to avoid 
the related events and situations which bring back shameful memories (142). However, with 
HIV infection, this is not possible, which may contribute to anxiety. People living with a disease 
related to sexuality may feel ashamed (144). Faith also plays a pivotal role in HIV shame, 
making it more pronounced in this population as most people see HIV as punishment for 
wrongdoing (143). Furthermore, having to take ARVs for the rest of their life and thinking of 
the outcome of the pregnancy may be anxiety provoking for pregnant women. All of these are 
stressful life events which may contribute to women feeling ashamed of their situation. 
Women who reported a lifetime experience of violence had higher odds of anxiety. This finding 
supports other previous publications (66,78,98). It is well-documented that long-term exposure 
to trauma, especially in childhood, may cause neurological changes. Such changes may lead to 
a malfunction of the brain, which in turn may lead to anxiety (145). On the other hand, 
individuals with mental illnesses like anxiety are at a higher risk of contracting HIV (146), 
resulting in the vicious cycle of HIV. Even with the existing evidence of prevalence and the 
consequences of violence against women, there is little attention in the PMTCT programme to 
address violence. The programme is structured around physical health while forgetting that 
mental health is a facilitator of physical health. Due to circumstances surrounding violence, the 
victims are unlikely to disclose such incidences. However, a close follow-up and rapport can 
enhance disclosing the violence. Furthermree, management of chronic infections such as HIV 
requires an holistic approach. 
Prevalence and factors associated with comorbidity 
Interestingly, in the present study, 18.1% of women met criteria for both possible depression 
and probable anxiety. Literature shows that the comorbidity of anxiety and depression is 
common among pregnant women, similar to the general population (10%) (81). However, the 
data in pregnant women living with HIV is limited. Nevertheless, the prevalence of comorbidity 
is consistent with previous studies (83,147). For example, one study in northern Tanzania found 
that anxiety and depression coexisted among pregnant women (148). Previous literature 
suggests that comorbidity is even more common compared to the presence of either depression 
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or anxiety alone, with up to 52% of patients diagnosed with depression also presenting 
symptoms of anxiety (83). Indeed, the overlap of the two mental illnesses was high in this 
population, with 72% of recruited women with possible depression also presenting with 
anxiety. 
A challenge is that sometimes patients with comorbidity do not present with typical symptoms 
(80). Of interest is that these disorders tend to mask each other, potentially due to the overlap 
in symptoms. Considering the poor disease outcomes in patients with comorbidity, if these 
women with comorbidity are not able to manage these disorders, they are likely to have poor 
disease outcomes as well as a poor quality of life (149). Even with mental illness treatment, the 
recovery among clients with comorbidity is slow. On top of slow recovery among people with 
comorbidity, their risk of progressing to chronic conditions and the rate of recurrence are also 
high (81). Consequently, if these conditions are not addressed as comorbid and with a holistic 
approach to management, the rates of treatment failure are likely to remain high (81). Validated 
screening tools that can be used to assess both anxiety and depression do exist (81). These 
screening tools are simple, which make them feasible for primary health care. Even at the stage 
which requires medications, there are single drugs with proven effectiveness for the two 
conditions (81,150). 
In the present study, HIV-related shame and lifetime experience of violence predicted 
comorbidity. Both the HIV-related shame and the lifetime experience of violence in these 
women were associated with possible depression and anxiety when considered separately. To 
begin with is the association between HIV-related shame and the comorbidity of possible 
depression and anxiety. As discussed previously, since HIV transmission is more related to 
sexuality, people infected feel that they have diverged from the norm. In addition, these women 
are coming from communities where people say bad things about infected people and expect 
the same to happen to them sooner or later (151). The findings are consistent with other studies 
(144). Women with a current or past history of experiencing violence were at increased risk of 
mental health disorders. Whereas the antenatal HIV testing is mandatory in women, in some 
parts, many men do not test during the same period (132). Commonly, women are blamed for 
introducing the disease into relationships because they tested first (152). Because of this, some 
marriages end in separation or divorce, and others may be the victims of violence (91). Because 
of these negative consequences, among others, some women choose to test alone while others 
opt not to disclose their status. All of these add up to the challenge of eliminating MTCT of 
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HIV and also the road toward ending the HIV epidemic. In order to achieve the world 
HIV/AIDS targets, more efforts are needed to overcome HIV-related shame and violence. 
5.2 Limitations 
Several limitations of this study must be considered when interpreting these findings. Firstly, 
the parent study enrolled only a subset of women attending the antenatal clinic who were 
referred to the study. While the parent study intended to screen all potential women, not all 
were referred from standard care to the research team. The characteristics of those not referred 
and not enrolled were not available for comparison, which makes it difficult to assess the 
selection bias. At the same time, there is a possibility of volunteer bias; women attending the 
clinic for PMTCT were informed of the ongoing study and only those who volunteered were 
referred for screening. Both these issues might have affected the reported prevalence and the 
measure of association. Therefore, the results of this study should be interpreted with some 
caution.  
Secondly, secondary data analysis was conducted, and limited to the number of participants 
enrolled in the parent study. We had calculated a minimum sample size of 300; however, the 
parent study only enrolled 200 participants meeting the criteria for this sub-study. With an 
underpowered sample, we may have failed to identify the associations of probable anxiety and 
possible depression to some important health-associated factors.  
Thirdly, pregnant women below 18 years were not eligible for participation, while adolescent 
pregnancy has been shown to be associated with mental health disorders. Excluding those 
below 18 years might have underestimated the prevalence of mental health disorders in this 
population.  
Fourthly, some of the assessment tools used have not been validated in Tanzania or translated 
into the local language (Swahili), which might have impacted our findings. In addition, using 
EPDS to detect depression at a cut-off score of 10 has high sensitivity at the cost of specificity. 
Conversely, some women might have been misclassified as depressed just because of the low 
cut-off point (a score on the EPDS of 10 and above) used in this study. With the possibility of 
systematic non-differential misclassification in the study, we might have underestimated the 
true association with depression.  
Fifthly, as mentioned earlier, depression and comorbid anxiety are common, even more than a 
single disorder. Most people with a comorbid condition present with atypical signs and 
symptoms. Because of this, screening for depression and anxiety independently is likely to 
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underestimate the prevalence. Instead, comorbidity screening tools such as the Primary Care 
Evaluation of Mental Disorder could have minimised this measurement bias. 
Sixthly, some of the exposure concepts are known to overlap with depression assessment tools. 
For example, both EPDS and HIV shame items measure worthlessness. This might have 
resulted in the observed association between HIV shame and the possible depression. 
Lastly, because of the nature of this study, it is difficult to rule out the reverse causality of 
mental illness and some factors. Of particular concern are the association between lifetime 
experience of violence and food insecurity, and mental health. While women with a history of 
experiencing violence are at risk of depression, depressed women are likely to experience 
violence. The same can happen with other factors, as mentioned in chapter 2. This study 
presents an opportunity for the ongoing cohort to assess whether the results from this baseline 
analysis are consistent with subsequent cohort data.   
5.3 Implications for policy, training and practice 
The chapter will conclude with implications for policy development, training, and practice, as 
well as offering recommendations for future studies. 
To begin with are the implications of the findings of the present study for policy in Tanzania. 
This study has demonstrated that mental illness is common in pregnant women living with HIV. 
Although common in this population, there are no clear strategies and guidelines for 
practitioners on how to screen, diagnose and manage these conditions. Additionally, the 
medications to treat depression and anxiety are not readily available at primary health care 
facilities, even though, in Tanzania, the majority of pregnant women living with HIV are 
managed at primary health care facilities. This could be an entry point to detect and treat 
depression and anxiety among this vulnerable population. Therefore, the Ministry of Health 
and the PMTCT programme could integrate mental health services into the routine PMTCT 
care. Developing clear strategies and guidelines on how to screen, diagnose and treat mental 
health among pregnant women living with HIV would facilitate this integration. Furthermore, 
the mental health strategy should address the availability of medication to treat anxiety and 
depression in all facilities that provide PMTCT services. In addition to the pharmacological 
considerations, psychological interventions may be more acceptable and affordable among 
PLHIV in LMICs. Although there is limited robust evidence on the efficacy of cognitive 
behavioural therapy (CBT) among PLHIV in LMICs  (153), CBT can improve HAART 
adherence and lower diseae progression (154). In this population of women presenting with 
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mild symptoms of common mental illness, they should be offered CBT before even considering 
pharmacological intervention. Nurses at the clinic can provide CBT for those screening positive 
and probably refer only clients who are severe or not responding. 
The findings of the present study have a number of implications for training. Similar to other 
LICs, in  Tanzania, the human resources available to address mental health are inadequate 
(155). Most of the mental health specialists are based in urban areas while the vast majority of 
the citizens are living in rural locations. This unmet need for mental health specialists, 
particularly in rural areas, is of concern, considering the presence of known risk factors for 
mental illness such as poverty and social disparities (138). Further efforts to train mental health 
specialists are urgently needed. However, training of more mental health specialists is a long-
term plan and training alone is not expected to resolve the current gap in the mental health 
workforce.  
To address this gap in the mental health workforce, WHO recommends a task sharing strategy 
(156). It is a process of delegation whereby tasks are moved, where appropriate, to less 
specialised health workers. Task sharing to non-specialist mental health providers can be in 
four levels: to the medical doctors, non-physician clinicians, nurses and community healthcare 
workers (157). Task sharing is not a new strategy. It was implemented successfully to address 
the HIV/AIDS epidemic. The WHO HIV “Treat, Train, Retain” plan not only offers task 
sharing recommendations, but also includes the implementation guidelines (158). For example, 
one review reported that in most African settings doctors delegated ART initiation and 
monitoring to nurses and other non-physician clinicians. As a result, more patients were being 
served and were receiving high-quality care. In addition, the review found that the delegation 
of ARV initiation and monitoring to nurses and non-physician clinicians was cost-effective 
(159). Additionally, in some countries, lay counsellors, including those living with HIV, have 
been instrumental in ART adherence counselling.  They provide both pre- and post-test 
counselling, follow-ups and home visits when necessary to enhance retention (160). 
Especially for mental health, task sharing non-specialist mental healthcare workers exclude 
psychiatrists, neurologists, psychologists, psychiatric nurses and mental health social workers. 
A recent review by Singla found that the common non-specialist mental health providers in 
primary health care facilities in LMICs were community healthcare workers (161). 
Furthermore, Petersen and colleagues in South Africa suggested that in a population of 100 
000, to achieve a minimal (30 to 50%) mental health service coverage, the primary health care 
 51 
staffing package should include one mental health counsellor and around seven community 
mental health workers (162).  
Although the evidence from LMICs shows that the task sharing approach has potential in 
delivering mental health services in primary health care, the challenge has been how to 
implement the mental health task sharing within HIV/AIDS care. With a well-established 
HIV/AIDS programme, the mental health task sharing can be enhanced by training HIV/AIDS 
providers and then delegating them to provide mental health care. With routine support from 
mental health specialists, mental health task sharing to the well-established HIV care will be 
more effective (156).  
A good model for both training and implementation of mental health care at primary care 
facilities is the one suggested by the WHO Mental Health Gap Action Programme (mhGAP) 
(163). The mhGAP was launched in 2008, aimed to scale up care for MNS disorders. The 
recommendations were later followed by the intervention guide in 2010, which suggests clinical 
steps for assessment and management of MNS disorders. Adequate and appropriate training is 
necessary for scaling up mhGAP MNS disorders, more importantly because care for these 
conditions depends more on providers’ knowledge and skills than technology or equipment. 
The mhGAP follows the “cascade” model of training with two levels: at the first level, the 
master trainers train trainers/facilitators, provide them with supportive supervisors, and ensure 
that they have the ability to train and support health workers. At the second level, the 
trainer/facilitator trains non-specialist healthcare providers on the assessment and management 
guidelines for MNS disorders. In addition, they coordinate supervision and support to health 
workers. Then, the non-specialist providers (NSP) implement the mhGAP Intervention Guide 
(mhGAP-IG) (164).  
Following the roll-out of mhGAP, there is vast evidence from LMICs of improvements in 
mental health case detection and management (165–167). For instance, in Nigeria, evidence 
shows that the case detection, reporting, and referrals of the four priority MNS disorders 
increased following training of NSP on the mhGAP-IG, whereas before the implementation, no 
cases were reported from primary healthcare providers in those facilities. There was an 
improvement in the general knowledge of mental illness among NSP, as well as an 
improvement in essential supplies of psychiatric drugs (166).  
In East African countries, studies in Ethiopia and Kenya reported a significant increase in the 
detection of mental illnesses following the implementation of mhGAP-IG. Additionally, 
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Ethiopia noted a significant increase in the number of trained mental health professionals and 
in mental health institutions (165,168). Despite a number of reported challenges, the integration 
of mental health into primary health care in Ethiopia looks promising. Tanzania and other East 
African countries can learn from the Ethiopian model of mental health task sharing. The mental 
health task sharing can help address the current mental health care among women living with 
HIV. This is of particular use, especially in this population with high comorbidity of depression 
and anxiety, as mhGAP separates depression from other mental illnesses. A recommendation 
regarding this is to have a transdiagnostic approach discussed early. 
Finally, the findings of the present study have a number of implications for practice. Firstly, in 
order to implement mhGAP at primary health care facilities, valid and reliable assessment tools 
are essential. However, as mentioned in the study limitations, the mhGAP outcome measures, 
such as depression measures, have not been validated in Tanzania. Furthermore, as presented 
in the results section, the comorbidity of mental illness was common, probably even more 
common compared with a single disorder. Although only a few, there are screening tools for 
comorbid anxiety and depression validated elsewhere for use in primary healthcare. Among the 
validated tools for primary health care are the Primary Care Evaluation of Mental Disorder, and 
the Symptom Driven Diagnostic System for Primary Care (81). However, these are just 
screening tools and they do not address the treatment of mental illnesses. A pragmatic feasible 
solution to the challenge of comorbidity and assessment tools is the transdiagnostic treatment 
approach (169). The transdiagnostic approach acknowledges the presence of comorbidity and 
that some of these disorders have some similarity in their pathophysiology. 
To implement the transdiagnostic treatment approach effectively, Bolton and colleague 
suggested the adoption of the Common Element Treatment Approach (CETA). By CETA, 
NSPs are trained to identify common elements within each disorder treatment package and how 
to tailor them to an individual. For example, since these disorders have cognitive and 
behavioural factors attached, identifying cognitive and behavioural factors and helping patients 
to make the right choices has been shown to be effective in managing depression and anxiety 
(170). CBT is also effective in managing patients with depression and anxiety (171). The 
management of the comorbidity with CBT is challenging; therefore, a symptomatic approach 
is recommended (171) ,with the therapy targeting the most severe symptoms.  
CBT can be used in addition to the pharmacological approaches (150). The results of one 
systematic review reported that nefazodone was effective in treating anxiety and depression 
(172). However, it is advisable to treat anxiety first, because patients with controlled anxiety 
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are more likely to adhere to antidepressants. In addition, selective serotonin reuptake inhibitors 
(SSRI) are considered the first line in treating comorbid depression and anxiety (81). 
Additionally, aripiprazole, quetiapine, and gabapentin, among others, are FDA-approved drugs 
for treating depression with comorbid anxiety. While some are effective alone, others such as 
gabapentin can be combined with SSRI to achieve maximum effectiveness (150). 
5.4 Conclusion 
In this population of women living with HIV, we found a high prevalence of possible depression 
and anxiety. Similarly, the prevalence of comorbidity of possible depression and probable 
anxiety was high. The majority of women who met the criteria for possible depression also 
screened positive for probable anxiety. In order to meet the target of elimination of MTCT of 
HIV, mental health-related issues need to be addressed with a similar emphasis to that of 
physical health. Unmarried women, women with a history of experiencing violence, women 
with food insecurity, and those who felt ashamed of their HIV had higher odds of mental illness. 
These factors are deeply rooted in the culture and beliefs, which emphasises the importance of 
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Study ID:    ___       ___ ___ ___ 
                                Clinic                 Individual ID  
 
Date of Survey: ___/ __ /___ 








If interview not held at clinic, indicate where: 


















5. St. Joseph 












Before beginning, say to participant: 
Nitakuuliza baadhi ya maswali juu yako mwenyewe. Hakuna majibu sahihi kwa maswali 
haya. Chagua jibu ambalo linaelezea nafsi yako vizuri zaidi. Tuko mahali faragha na 
hakunamtu atasikia majibu yako, na nitazitunza kwa siri. Unaweza kutokujibu swali lolote 
ambayo utaki kujibu, na unaweza kupumzika au kuacha kujibu maswali muda wowote. 
Usipo elewa swali, tafadahli niambie. Ni muhimu sana kujibu maswali yote kwa uaminifu. 
Je, una swali lolote kabla atujaanza? 
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Basic Demographics 




Do you live in Moshi town? 1.    Yes 
2.     No  
DEM3 
If living in Moshi: What ward do you 
live in?  
 
DEM4 








_____ years  _____ months 
DEM6 
How do you typically travel from 
your home to this clinic? 
1.   Walk (skip to DEM9) 
2.    Dala dala 
3.    Boda boda 
4.    Private car / Taxi 
5.    Other: _______________ 
DEM7 How much does it cost you to travel from your home to this clinic?  
__________ TSh 
DEM8 
Who pays for your transport cost from 
your home to the clinic?  
1.    Myself 
2.    My husband 
3.    Relative 
4.    Other, specify: ___________ 
DEM9 
How long does it take you to get from 
your home to this clinic?  
  
_____ hours ______ minutes 
DEM10 
What is your religion?  1.    Christian, denomination:  
_____________________ 
2.    Muslim 
3.    No religion 
4.    Other religion:  
_________________ 
DEM11 
What is the highest level of school 
that you completed?  
1.    No formal education  
2.    Primary education (specify level 
attained: ________) 
3.    Secondary education (Specify 
level attained:  
        ______________________) 
4.    Higher education (Specify field:  
        _____________________) 
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DEM12 What best describes your current relationship status?  
1.    Married 
2.    Single, not in a relationship  
3.    In a relationship, but not married 
4.    Separated from spouse/ Divorced 
5.    Widow 
DEM13 
If currently married or in a 
relationship: Is this person the father 
of the child you are pregnant with? 
1.   Yes 
2.   No 
3.   Don’t know 
DEM14 Do you currently live with your partner? 
1.   Yes, all the time 
2.   Yes, sometimes 
3.   No 
4.   Not in a relationship  
DEM15 If married: Are you in a polygamous relationship? 
1.   Yes 
2.   No 
DEM16 What is your partner/husband’s highest level of education? 
1.    No formal education  
2.   Primary education (specify level 
attained: ________) 
 
3.    Secondary education (Specify 
level attained:  
        ______________________) 
4.    Higher education (Specify field:  
        _____________________) 
Socio-Economic status 
SES1 
Does the house where you live have 
electricity?  
1.    Yes 
2.    No 
SES2 
Does the house where you live have 
piped water inside?  
1.    Yes 
   2.    No 
SES3 Do you own a cell phone? 1.    Yes    2.    No 
SES4 
Are you currently working in any 
sector where you receive a regular 
monthly salary?  
1.    Yes 
   2.    No 
SES5 




If you are not formally employed, 
what do you do to earn an income?  
1.    No income-earning activities 
2.    Big farmer 
3.    Peasant farmer 
4.    Business 
5.    Petty trader 
6.    Other, specify:  
       _______________________ 
SES7 
If any work: How much money do you 
earn per month from these activities? 
(on average) 
 
__________________ TSh.  
SES8 
If in a relationship: Does your 
husband/partner work in a sector 
where he receives a regular monthly 
salary? 
1.    Yes (Skip to SES10) 
2.    No 
3.    N/A, not in a relationship (Skip to 
SES11) 
SES9 
If he’s not formally employed, what 
does he do to earn an income?  
1.    No income-earning activities 
(Skip to SES11) 
2.    Big farmer 
3.    Peasant farmer 
4.    Business 
5.    Petty trader 
6.    Other, specify:  
       _______________________ 
SES10 
How much money does your 
husband/partner earn per month, on 




Who provides the primary financial 
support in your household? 1. Myself 2. Husband 
3. Parents / In-laws 
4. Others, specify _________ 
Pregnancy history 
PREG1 




Is this the first time you have been 
pregnant? 
1.    Yes (Skip to HIV1) 
2.    No 
PREG3 
Before this, how many times have you 





Mode of develivery in the previous 
pregnancy  
1. SVD 
2. Caesarian section 
3. Forceps 
4. Episiotomy  
5. Other, specify …….. 
If other times she’s been pregnant: 
What was the outcome of those other pregnancies? (shaded boxes should add up to PREG3) 
PREG5 
Number of children who are still 
alive. 
(If 0, skip to PREG7) 
 
PREG6 
Are any of those children HIV-
positive? 
(Write number who are HIV+; if 
none, write 0) 
 
PREG7 
Number of (spontaneous) 
miscarriages (<20 weeks) 
 
PREG8 
Number of still births (>20 weeks)  
PREG9 
Number of (induced) abortions   
PREG10 
Number of children who have died (in 
infancy, childhood, or adulthood) 
(If 0, skip to PLAN1) 
 
PREG111 
Were any of those children who died 
HIV-positive? 
(Write number who are HIV+; if 




When did you first learn that you were 
HIV-positive? 
1.    During this pregnancy (skip to 
HIV3) 
   2.    Before this pregnancy 
HIV2 
If before this pregnancy: What 
motivated you to go for test? 
1. Illness 
2. VCT 
3. Previous pregnancy  
4. National campaign 
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5. Others, specify _________ 
HIV3 
What was the date when you learned 
that you were HIV-positive? 





Has your partner / husband been 
tested for HIV? 
1.    Yes  
   2.    No (skip to DEM6) 
   3.    Don’t know (skip to DEM6) 
HIV5 
If tested: What was the result of his 
most recent HIV test? 
1.   HIV-positive 
2.   HIV-negative 
3.   Don’t know 
For the next 5 items, ask to see the patient’s HIV clinic card. (Only for clients who agreed 
for their cards to be reviewed)  
HIV6 
What was your latest CD4 count 
count? 
(check patient card) 
________ cells/mL 
   8.  Card not available 
   9.  No CD4 test result recorded  
HIV7 
Nadir/lowest CD4 count  
(check patient card) 
______ cells/mL 
   7.  Only one CD4 test result recorded 
   8.  Card not available 
   9.  No CD4 test result recorded 
HIV8 
Viral load 
(check patient card) 
_____________  
   8.  Card not available 
   9.  No viral load test result recorded 
ARV history 
ARV1 
What ARV regimen are you currently 
using?  
(check patient card or pill bottle) 
1.  TLE (Tenofovir, Lamivudine and 
Efavirenz) 
2.  Other: ______________ 
8.  Information not available 
ARV2 
When did you start taking ARVs?  
(check patient card, or provide 
patient’s best estimate) 
____ / ____ / ____ 
dd      mm       yy 
8.  Information not available 
ARV3 
Prior to this pregnancy, have you ever 
used any ARVs? 
1. Yes 
2. No (skip to next section) 
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ARV4 
Have you used ARVs during a 
previous pregnancy? 
1. Yes 
2. No  
ARV5 
Have you ever received ARVs at a 




Modified Household Food Insecurity Access Scale (FHI) 
 
Description: I am now going to ask you some questions about your household, and how easy 
or difficult it is to get the food you need. 
 
FHI1 In the past month, how often could you not feed your family? 
0.    Never 
1.    Once or twice 
2.    More than once or twice but not 
every day 
3.    Every day 
FHI2 
In the past month, how often were you 
hungry, but did not eat because you could 
not afford enough food? 
0.    Never 
1.    Once or twice 
2.    More than once or twice but not 
every day 
    3.    Every day 
FHI3 
In the past month, how often did you or 
other adults in your household not eat for 
a whole day because there was not 
enough money for food? 
0.    Never 
1.    Once or twice 
2.    More than once or twice but not 
every day 
3.    Every day 
FHI4 
In the past month, how often did you or 
other adults in your household cut the 
size of your meals because there was not 
enough money for food? 
0.    Never 
1.    Once or twice 
2.    More than once or twice but not 
every day 
   3.    Every day 
 
Depression: Edinburgh Postnatal Depression Scale (EPDS) 
Description: As you are pregnant, we would like to know how you are feeling. Please listen to 
each statement. I will then read some answer choices. I’d like you to select the answer  
that comes closest to how you have felt in the past 7 days, not just how you feel today.  
 
 
EPDS1 I have been able to laugh and see the 
funny side of things.* 
0.   As much as I always could 
1.   Not quite so much now 
2.   Definitely not so much now 
3.   Not at all 
EPDS2 I have looked forward with 
enjoyment to things.* 
0.   As much as I ever did 
1.   Rather less than I used to 
2.   Definitely less than I used to 
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3.   Hardly at all 
EPDS3 I have blamed myself unnecessarily 
when things went wrong. 
0.   Yes, most of the time 
1.   Yes, some of the time 
2.   Not very often 
3.   No, never 
EPDS4 I have been anxious or worried for 
no good reason. 
0.   No, not at all 
1.   Hardly ever 
2.   Yes, sometimes 
3.   Yes, very often 
EPDS5 I have felt scared or panicky for no 
very good reason. 
0.   Yes, quite a bit 
1.   Yes, sometimes 
2.   No, not much 
3.   No, not at all 
EPDS6 Things have been getting on top of 
me. 
0.   Yes, most of the time I haven’t been 
able to cope at all 
1.   Yes, sometimes I haven’t been coping 
as well as usual 
2.   No, most of the time I have coped 
quite well 
3.   No, I have been coping as well as ever 
EPDS7 I have been so unhappy that I have 
had difficulty sleeping. 
0.   Yes, most of the time 
1.   Yes, sometimes 
2.   Not very often 
3.   No, not at all 
EPDS8 I have felt sad or miserable. 0.   Yes, most of the time 
1.   Yes, quite often 
2.   Not very often 
3.   No, not at all 
EPDS9 I have been so unhappy that I have 
been crying. 
0.   Yes, most of the time 
1.   Yes, quite often 
2.   Only occasionally 
3.   No, never 
EPDS10 The thought of harming myself has 
occurred to me. 
0.   Yes, quite often 
1.   Sometimes 
2.   Hardly ever 
3.   Never 
 
Anxiety: BSI Anxiety Subscale (BSI) 
Description: I am going to read a list of problems people sometimes have. Please listen to each 
one carefully and tell me how much that problem has distressed or bothered you during the past 
7 days, including today. 
 





Moderately Quite a bit Extremely 
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BSI1 Nervousness or shakiness inside. 0 1 2 3 4 
BSI2 Feeling tense or keyed up. 0 1 2 3 4 
BSI3 Suddenly scared for no reason. 0 1 2 3 4 
BSI4 Spells of terror or panic.  0 1 2 3 4 
BSI5 Feeling so restless you couldn’t 
sit still. 
0 1 2 3 4 
BSI6 Feeling fearful.  0 1 2 3 4 
 




Have you ever been diagnosed with any mental 
illness? 
1.  Yes 
2.  No 
3.  Don’t know 
HXMI2 What is the name of the mental illness?  
 
 
3.  Don’t know 
 
Alcohol use: AUDIT-C (AUDIT) 
Description: Now I am going to ask you some questions about your use of alcoholic beverages 




How often did you have a drink containing alcohol? 0.    Never (skip to next 
section) 
1.    Monthly or less 
2.    2-4 times a month 
3.    2-3 times a week 




How many standard drinks containing alcohol did 
you have on a typical day?  
NOTE: One drink is equal to 1 can or small bottle 
of beer, 1 glass of wine, 1 shot of spirits or liquor, 
or 1 serving of local brew.  
0.    1 or 2 
1.    3 or 4 
2.    5 or 6 
3.    7, 8, or 9 
4.    10 or more 
AUDIT3 
 
How often did you have 6 or more drinks on one 
occasion? 
0.    Never 
1.    Less than monthly 
2.    Monthly 
3.    Weekly 
4.    Daily or almost daily 
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 The HIV- and abuse-related shame inventory Shame Inventory (HARSIH) 
Description: I am going to read a list of statements describing feelings that many people with 











Somewhat Quite a bit 
Very 
much 
HARSIH1 It is hard to tell other people about my infection. 0 1 2 3 4 
HARSIH2 I have failed to live up to my own expectations by getting HIV. 0 1 2 3 4 
HARSIH3 When I tell others I have HIV, I expect them to think less of me. 0 1 2 3 4 
HARSIH4 I put myself down for becoming HIV+. 0 1 2 3 4 
HARSIH5 
 
Being HIV+ makes me feel 
defective, like there is something 
wrong with me. 
0 1 2 3 4 
HARSIH6 I am ashamed that I'm HIV+. 0 1 2 3 4 
HARSIH7 When others find out I am HIV+, I expect them to reject me. 0 1 2 3 4 
HARSIH8 I struggle with feeling worthless because I have HIV. 0 1 2 3 4 
HARSIH9 I am ashamed by my HIV symptoms. 0 1 2 3 4 
HARSIH10 I hide my infection from others. 0 1 2 3 4 
HARSIH11 
 
I have an overpowering dread that 
my HIV status will be revealed to 
others. 
0 1 2 3 4 
HARSIH12 I accept myself as an HIV+ person. 0 1 2 3 4 
HARSIH13 Having HIV makes me want to hide, disappear, or even die. 0 1 2 3 4 
 
Attitudes about pregnancy: Adapted from Guttmacher measure (PREGAT) 
Description: I’m going to read you some statements about how you may feel about your 
pregnancy. Please listen to each statement and tell me how much you disagree or agree with 
each statement. 
 
  Strongly Disagree Disagree Agree 
Strongly 
Agree 
PREGAT1 This pregnancy is a result of a plan I made to get pregnant.  0 1 2 3 
PREGAT2 Before getting pregnant, I knew that I wanted to have a baby. 0 1 2 3 
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PREGAT3 When I learned I was pregnant, I felt happy. 0 1 2 3 
PREGAT4 I looked forward to telling my friends that I was pregnant. 0 1 2 3 
PREGAT5 This pregnancy came at the right time of my life. 0 1 2 3 
PREGAT6 My partner wanted me to become pregnant. 0 1 2 3 
PREGAT7 I feel happy about being pregnant. 0 1 2 3 
PREGAT8 
If I could do it all over again, I 
would still choose to be pregnant at 
this time.  
0 1 2 3 
 
Perceived Availability of Social Support (PAS) 
Description: The following questions have to do with the support you get from people in your 
life. I’m going to read you a series of questions about the different types of help people might 
give you. Please tell me whether someone would be available to provide that kind of help or 
support if you needed it. Remember that I’m not asking whether or not you need this kind of 













Would someone be 
available to talk to you 
if you were upset, 
nervous, or depressed? 
1 2 3 4 5 
PAS2 
 
Is there someone you 
could contact if you 
wanted to talk about an 
important personal 
problem you were 
having? 
1 2 3 4 5 
PAS3 
 
Is there someone who 
would help take care of 
you if you had to stay in 
bed for several weeks? 
1 2 3 4 5 
PAS4 
 
Is there someone you 
could turn to if you 
needed to borrow 2,000 
TSh, needed to get a 
ride to the doctor, or 
needed some other 
small immediate help? 




Is there someone you 
could turn to if you 
needed to borrow some 
money to help pay your 
rent for one month? 
1 2 3 4 5 
PAS6 
Would the people in 
your personal life give 
you information, 
suggestions, or 
guidance if you needed 
it? 
1 2 3 4 5 
PAS7 
 
Is there someone you 
could turn to if you 
needed advice to help 
make a decision? 
1 2 3 4 5 
PAS8 
 
Is there someone who 
could take care of your 
children if you got 
sick? 
1 2 3 4 5 
 
HIV Disclosure (HIVD) 
Description: I would now like to hear about your experience talking to people in your life about 
your HIV status. If you have not talked to anyone about your status, or don’t have plans to talk 
to anyone about your status, that is completely understandable and it is fine to say so.  
 
 No Yes 







 No Yes N/A 
HIVD2 Have you told your partner/husband? 0 1 2 
HIVD3 Have you told any other sexual partners?  
[If no other sexual partners, choose N/A] 
0 1 2 
HIVD4 Have you told any family members? 0 1 2 
HIVD5 Have you told any friends? 0 1 2 
HIVD6 How soon after learning your HIV status did you first 
disclose your HIV status to someone outside of this 
clinic? 
 









HIVD7 In the last 3 months, has your HIV status ever been told 
to someone else without your consent? 
1.  Yes 
2.  No  
HIVD8 In the last 3 months, have you experienced any negative 
reactions after you told someone your HIV status? 
1.  Yes 
2.  No 
3.  N/A 
 
Enacted Stigma: HIV/AIDS Stigma Instrument (HASI) 
Description: I’m going to read a list of events that may have happened to you because you are 
living with HIV. Please tell me in the past 3 months, how often each of these things happened 
to you because of your HIV status. 
 









HASI1 I was asked to leave because I was 
coughing. 0 1 2 3 
HASI2 Someone stopped being my friend. 0 1 2 3 
HASI3 I was called bad names. 0 1 2 3 
HASI4 I was made to eat alone. 0 1 2 3 
HASI5 Someone insulted me. 0 1 2 3 
HASI6 People avoided me. 0 1 2 3 
HASI7 People cut down visiting me. 0 1 2 3 
HASI8 People ended their relationships with 
me. 0 1 2 3 
HASI9 I was blamed for my HIV status. 0 1 2 3 
HASI10 My ability to earn money was 
impacted. 0 1 2 3 
HASI11 People gossiped about me. 0 1 2 3 
INTERPERSONAL VIOLENCE (VIOL) 
Description: Here is a list of questions about how often you have experienced different types 
of violence, both when you were a child and now as an adult. Please listen to each question 
carefully and tell me whether you have ever had this experience. 
 
  Yes No 
VIOL1 Has a spouse/partner ever insulted you or 
called you bad names? 
1 2 




  Yes No 
VIOL3 Has partner/husband ever hit, slapped or hurt 
you physically in any other way? 
1 2 
VIOL4 IF YES: Has this happened in the last 3 
months? 
1 2 
VIOL5 As an adult, has someone ever forced you to 
have sex when you didn’t want to? 
1 2 
VIOL6 IF YES: Has this happened in the last 3 
months? 
1 2 
VIOL7 As a child, were you ever forced to have some 
kind of sexual contact, touching, oral sex, or 
intercourse? 
1 2 
HIV care engagement 
Description: For many people it is difficult to attend every medical appointment. The following 
questions ask you about your experiences going to HIV/wellness clinic appointments.  
 
  No Yes 
VISIT1 
In the PAST 3 MONTHS, have you attended any appointments in the 
HIV / PMTCT / antenatal care clinic?  0 
1 
VISIT2 




In the PAST 3 MONTHS, how many times have you MISSED your 
originally scheduled clinic appointment?  
 
VISIT4 
In the PAST 3 MONTHS, how many times have you RESCHEDULED 












burden OR Prevalence OR Prevalences OR Frequency OR 
Proportion OR Incidence OR epidemiology 3441956 
#2 
Depressions OR Depressive Symptoms OR Depressive Symptom 
OR Symptom Depressive OR Symptoms Depressive OR 
Emotional Depression OR Depression Emotional OR Depressions 
Emotional OR Emotional Depressions  355660 
#3 
factors OR factor OR risk factor OR risk factors OR determinants 
OR determinant OR predictor OR predictors OR population at risk 
OR risk population 5007254 
#4 
pregnant OR pregnant OR pregnancy OR pregnancies OR 
antenatal OR prenatal OR natal OR prenatal OR partum OR 
antepartum OR prepartum OR peripartum OR "mother-to-child 
transmission" OR "vertical transmission"  946007 
#5 
HIV AIDS OR HIV/AIDS OR HIV OR AIDS OR PMTCT OR 
people living with HIV OR human immunodeficiency virus OR 
acquired immunodeficiency syndrome 419490 
#6 #1 OR #2 7105894 
#7 #6 AND #3 106739 
#8 #7 AND #4 5345 
#9 #8 AND #5 153 
Filters     
Human only   153 
Full text available   153 
languages   153 
      
  Anxiety    
#1 
burden OR Prevalence OR Prevalences OR Frequency OR 
Proportion OR Incidence OR epidemiology 3442201 
#2 
factors OR factor OR risk factor OR risk factors OR determinants 
OR determinant OR predictor OR predictors OR population at risk 
OR risk population  5007254 
 86 
#3 anxiety OR Anxieties OR Hypervigilance OR Nervousness  190416 
#4 
pregnant OR pregnant OR pregnancy OR pregnancies OR 
antenatal OR prenatal OR natal OR prenatal OR partum OR 
antepartum OR prepartum OR peripartum OR "mother-to-child 
transmission" OR "vertical transmission"  9460048 
#5 
HIV AIDS OR HIV/AIDS OR HIV OR AIDS OR PMTCT OR 
people living with HIV OR human immunodeficiency virus OR 
acquired immunodeficiency syndrome 419490 
#6 #1 OR #2 7105894 
#7 #6 AND #3 87930 
#8 #7 AND #4 4428 
#9 #8 AND #5 101 
Filters     
Languages-English   90 
  Human 75 
  Full text 62 
 
 
